

October 10, 2008

EEOICPA LIABILITIES as of SEPTEMBER 30, 2008

PURPOSE

Quality Casualty Consulting (QCC) has been retained by the US Department of Labor (DOL) to estimate liabilities of the government to pay claims under the Energy Employees Occupational Illness Compensation Program Act (EEOICPA). The liabilities are as of the end of the latest fiscal year ending 9/30/08.

This evaluation is for both Part B, which became effective July 31, 2001, and Part E which became effective October 29, 2004. The estimation is based as much as possible on actual experience under the program. It includes no estimate of administrative costs.

Although claims are projected to emerge in the future, we consider only those based on employments before 9/30/08. There is no liability calculated for exposure to toxic substances after 9/30/08. There is also no estimate of liability that may result from future law or administrative changes. The estimate does not include any loss adjustment expenses.

CONCLUSIONS

We have estimated liabilities under Part B of the EEOICPA as of 9/30/08 to be \$4,043,713,292, discounted by an interest rate of 4.770%. On an undiscounted basis, the liability is \$6,236,610,079. These numbers are shown in Exhibit 1.

At the end of fiscal year 2007, the Part B liabilities were \$3,611,342,318 discounted by an interest rate of 5.078% and \$5,353,306,109 on an undiscounted basis. The estimate of liabilities has increased since the end of last year primarily due to the addition of more new SEC classes and a lower rate used to discount losses.

Liabilities under part E of the Act are estimated to be \$4,055,605,311 discounted by the rate above, and \$6,829,426,204 on an undiscounted basis.

At the end of 2007, the Part E liabilities were estimated to be \$3,890,495,520 discounted by the rate above, and \$5,719,567,990 on an undiscounted basis. The liabilities have increased predominantly due to an assumption of a lower decay rate in reported claims for Part E. We also added 10 years to the projection period since the lower decay rate implied that more claims would be reported in future years.

These conclusions reflect the incorporation of comments on our draft model made by staff of the Department of Labor. The estimate of liability is an actuarial central estimate, an estimate that represents an expected value over the range of reasonably possible outcomes. There are no recoverables for this coverage.

BACKGROUND ON THE EEOICPA

Under Part B, the act provides a lump sum "indemnity" award of \$150,000 and medical benefits to living claimants who were employed in various energy-related activities either directly for the Department of Energy (DOE), or its contractors and sub-contractors. Claimants may include the survivors of deceased workers who would have been eligible for the awards and, in that case, the lump sum is divided among eligible survivors.

Coverage is coordinated with benefits to certain uranium workers under the Radiation Exposure Compensation Act (RECA). Individuals who have received, or will receive, the \$100,000 indemnity benefit under that act are presumed eligible for a \$50,000 indemnity award under the EEOICPA to "top up" the RECA benefit. Benefits have been transferred by the 2004 amendments so that RECA ground-up payments, including medical, have been assumed by the DOL under the EEOICPA.

Except for some broadening of coverage in the coordination with RECA, Part B coverage is for certain specified diseases only: cancer due to radiation exposure, and beryllium disease or silicosis related to exposure to those elements. These must be related to exposures at covered employment and exposures must satisfy certain temporal requirements. Special cases, workers with beryllium sensitivity, qualify for only certain medical benefits.

In a significant expansion of coverage to employees of contractors and subcontractors of the government, Part E was also added to the act, effective October 29, 2004. This extends federal compensation and medical benefits in lieu of state workers compensation benefits for injury and lost income of workers who developed occupational illness as a result of exposure to a broader selection of toxic substances at a DOE facility. This replaced Part D, which provided help to these workers in obtaining state benefits. Old Part D claims have been transferred to the new Part E program. Many claimants already accepted under Part B and RECA will be considered eligible for Part E benefits.

There are detailed requirements, which are only outlined below, that must be fulfilled in order to qualify for benefits under Part B. It should be noted that workers from certain specific locations are in the Special Exposure Cohort (SEC) and have been given favorable status towards acceptance. The SEC is workers at specific locations before February 1, 1992 who worked at least 250 days and have developed certain specific types of cancer.

Claimants must not be suing the government in tort nor be convicted felons. To receive awards, claimants must accept the lump sum payment in full for all claims against the US, DOE and its contractors and sub-contractors. For the purposes of this evaluation, we have assumed that all claimants will accept the EEOICPA award, dropping any lawsuits that may be pending.

THE DATA

Data that has been made available to us are extracts made to our specifications from a database constructed by the program administrators. There are several tables of data, many of which relate to details of the administration of the claims and are not relevant to our estimation. The tables with information useful in the estimation of liabilities contain key information on case (employee) and several with information by claim (which may be either the living employee or one or more of his/her survivors). Extracts requested by us include information on the employee (such as birth date, date of death, and disease), claimant (such as relationship, time of filing and payment), and claim status (relating to eligibility and possible administrative decisions to accept or deny.) We also obtained information on medical condition, claims with SEC status, and payments. These extracts were done as of July 2008. By using our model, we were able to project to an evaluation as of 9/30/08.

In addition to the above extracts, we were able to obtain information on EEOICPA medical payments by case from inception to 7/08.

We do not have a count of workers by year or location that have been exposed to dangerous substances.

OVERVIEW OF THE ANALYSIS

The general approach to evaluating Part B has been to estimate ultimate case count by medical condition, or disease, and extend that by the dollar value of the indemnity award, \$150,000. The critical injury types in this case are covered cancers, beryllium disease and chronic silicosis. Beryllium sensitivity is subject to medical awards only, and these cases were separated out. RECA cases which originated from a different program were also separated out.

To best use the available experience, we have done the estimate of future compensation respective of disease. We also separated out medical payments, which will have a different payment pattern than compensation.

Using the RECA indicator field, we first separated out cases resulting from coordination with the Radiation Exposure Compensation Act (RECA), which are mostly radiation-induced cancer and other lung diseases. Prior to the October 2004 changes, these were subject to a \$50,000 award per case under EEOICPA. Since it is expected to have a different administration and acceptance rate, RECA is treated as one of the qualifying diseases and these cases are separated out first. As a result of the October 2004 changes, new RECA cases will be paid the full \$150,000 under EEOICPA.

Prior to 2007, the \$100,000 per case paid on behalf of the DOJ on RECA cases was not included in our paid data. This year and last year, however, we obtained data on payments on behalf of the DOJ for RECA cases from a separate data base and were able to add these amounts to the \$50,000 per case paid by the DOL to obtain the total amount paid. This year, as in the past several years, the projection of liability for RECA cases use \$150,000 per case and thus incorporates both the \$50,000 per case payable under the original Part B and the additional amounts payable on behalf on the DOJ.

We assign cases to medical condition in the following priority order: RECA, cancer SEC, beryllium disease, chronic silicosis, cancer other than SEC and beryllium sensitivity. If more than one condition appeared for any given case, we used that order to slot the case.

Using the data from our extract, we projected the pattern and ultimate number of reported Part B cases by disease using an exponential decay model. Included in this projection is the emergence pattern for cases, that is, the number of cases projected to be filed each quarter for 22 years into the future.

We did not directly model the detailed process by which these diseases are judged to qualify for an award, but, based on sample recommendation and final approval rates, we selected estimates of the approval rate for cases of each disease.

Separate files were provided for Part E claims with dates, status and payment amount, allowing overlap with Part B claims just as awards are allowed to overlap. At this point, dividing Part E cases by disease seems unnecessary. We projected future emergence of cases in much the same way as for Part B cases. We also used information on the payments to date to estimate an average Part E indemnity award. For Part E we projected cases to be filed each quarter for 37 years into the future adding 9 years over last year's projection period.

Although at some time in the future we may be able to differentiate the two, this year we continued to make a single estimate of average annual medical benefits for both Part B and Part E. Medical payments are recorded to case and for cases approved under both Part E and Part B, the medical payments cannot be distinguished. We used a similar method to that of the DOL for allocating medical payments to Part B and Part E. Medical is counted as Part E only if there is no Part B claim or if the Part B claim is denied and the Part E claim is approved. Medical data is presented in Exhibit 2.

For Part B, we estimated quarterly average medical benefit per living employee with an approved case. This average medical benefit is taken over a broader base of employees and is thus smaller than the average medical amount paid to claimants actually receiving benefits. We calculated averages for Part B in total and for each of the larger disease categories: RECA, cancer SEC and cancer non-SEC. We also calculated an average medical for beryllium disease, chronic silicosis, and beryllium sensitivity combined. The average annual benefit is four times the quarterly.

Since many Part E claims are also approved under Part B, we apply a factor to the Part E medical to avoid double counting medical costs. This factor is 40%, the same as last year. The medical data reported to date shows that the average quarterly Part E medical cost per case is 63% of the average quarterly cost per case for Part B (\$1086/\$1728) and 48% of the selected quarterly medical cost per case (\$1086/\$2250). The Part E medical per case appears to be trending downward so we selected a lower than indicated provision.

We also projected the numbers of eligible employee claimants living during each future quarter who could receive ongoing medical benefits. The product of the average medical benefit and the number of eligible employees is the projected medical benefit.

After projecting the number of claims that will be filed and approved, we estimate how long after the claims are filed that they are paid to determine the compensation payment pattern. The number of claims paid times the average benefit is the amount paid.

DETAILED METHODOLOGY

Since the full award inures to the case, not the claim, we consolidated the data to a case basis. We segregated cases by disease using claim data, and we prioritized diseases so that cases coded to multiple diseases could be assigned to one disease.

A. Construction of database

For Parts B and E combined:

From the case (.cas) table, we extracted date of birth, date of death, and sex.

Medical amounts paid by case were provided in a table of medical benefits.

For each Part, B and E separately:

From the claim (.claim) table, we determined the case number, the date filed (earliest claim filed), if the claim was for employee, survivors or both, and if the claim was RECA.

From the medical condition table (.med_condition), we determined the disease using the primary medical condition code. We used a priority order if there was more than one disease listed. The priority was as follows: RECA, cancer SEC, beryllium disease, chronic silicosis, cancer non SEC, beryllium sensitivity, other lung, renal, other, 99 (Other Conditions, Not Listed) and blank. This was used to stratify the cases.

From the claim status table (.claim_status_history), we determined an approval status of each case. We recorded if Final Adjudication Branch (FAB) affirmed or denied an underlying claim, if approval was recommended or denied by the district administrators, or if it were closed. By assumption, approval of one underlying claim inured to the case.

Paid dates and amounts were taken from the payment (.payment) table. From claim payment data we received, we combine amounts paid by claim to case for each full quarter up to the one ending 6/08.

For Part B only:

If a claim is indicated as SEC in the SEC table (.emp_sec) or has an “SE” in the status history table (.claim_status_history), the claim was classified as SEC. If any underlying claim was SEC, then the case was so coded as SEC in our database.

This year, as last year, we have obtained all amounts paid by the DOL on behalf of the DOJ for RECA claims. This is \$100,000 per RECA claim. These amounts are summarized by date paid and added to the \$50,000 per claim paid on RECA claims in the database.

For Part E only:

From the acceptance of payment table, the breakdown of payment by lump sum, wage loss, and impairment was determined.

B. Estimating an emergence pattern of paid cases, respective of disease

1. Estimate the ultimate number of reported cases and an emergence pattern by disease.

Using this model, we estimate ultimate number of reported cases, as well as a pattern of reporting.

We start with the reported case count as of the latest full evaluation, 6/30/08. Using case counts reported by quarter, we determine a reporting pattern. Using an exponential decay model we determine how many cases are expected to be filed (in a statistical sense) in each of the upcoming quarters. Projections based on the fitted exponential decay model imply few cases will be filed after 2030 for Part B and after 2045 for Part E. We limit the number of years in our case projection exhibits to 22

for Part B and 37 for Part E, not including the 7 completed years. Medical payments are projected out over 50 years. Beyond this time there will undoubtedly be payments, but far fewer and highly discounted for interest. Most of the cases involve workers in their sixties, so these time frames are not unreasonable.

Before fitting the exponential model, some judgment was necessary to adjust quarters with an apparent excess of reported cases, typically the first quarter of the program, which was the third quarter of 2001. There presumably was a backlog of cases brought out by the new program. We excluded this quarter. We also judgmentally adjusted the fitted parameters to be reasonable and consistent with each other across diseases.

2. Estimate the number of reported cases that will be approved and paid. This we have done using approval rate statistics by disease that we derived from the status history table, so that a sample rate of approval is the number of approved cases divided by the total (approved + disapproved). We look at approval rates based on both the divisional recommendations and the Final Adjudication Branch (FAB).

C. Estimating a payment pattern

1. We start with the emergence pattern estimated as described in Section B.1 above. We assumed approved RECA and CN-SEC cases are paid one year after they are reported with a two-year lag for all other Part B diseases. For Part E we assume a two year lag from filing to approval and two year duration of payments. For some diseases, the payout assumptions lead to a large number of cases to be paid in the year following the estimate. To avoid this lump of cases, we spread the difference between the estimated approved cases and the number paid to date over five years for RECA, BD, and CN-NONSEC cases, 2 years for CN-SEC (70% to the first year and 30% to the second) and one year for CS.

For Part E the correction term is spread over 10 years. This procedure still left a large number of Part E cases to be paid in fiscal year 10/08-9/09. To correct this, we judgmentally deducted 600 Part E cases from the 10/08-9/09 fiscal year and added 600 cases to fiscal year 10/09-9/10. This is basically saying that some of the backlog of approved cases will be paid an additional year later. This adjustment does not significantly affect the total undiscounted compensation liability estimate but it affects the projected payout and discounted liability estimate which depends on when the cases are paid.

2. Compensation payment amounts are \$150,000 for part B cases. (RECA payments, which were once only \$50,000, are now also projected at \$150,000). For Part E, we estimated an average award of \$143,000 using analysis described in Exhibit 3, page 5.

3. Medical payment amounts are derived by estimating an average benefit award per eligible employee and a projection of how many such employee claimants are living in each year after the current. We selected \$9,000 for both Parts B and Part E, the same as last year. This is higher than the current average for Part B but we expect future claims will be more RECA and CN-SEC which have higher than average medical costs. Part E medical costs have been fluctuating significantly so we have selected Part E medical to be the same as Part E.

For projecting future medical payments, we also retained our estimate of medical inflation at 6%.

4. To project living employee claimants, those eligible for medical benefits, we used mortality rates for existing disabled male retirees from the RP-2000 Mortality Tables published by the Society of Actuaries, as well as our model estimate of new claimants emerging.

DESCRIPTION OF EXHIBITS

Exhibit 1, page 1 - The Estimate of EEOICPA Liabilities.

Usually liability is computed as the ultimate incurred minus paid loss to date, where loss is compensation plus medical. In this case, we used our model of the payment stream by disease and directly summed payments starting 10/01/08. We also calculate discounted liabilities using our payment pattern from Exhibit 6 and an interest rate of 4.770%.

Exhibit 1, page 2- Assumptions used in the calculations

The assumptions are related to discount rate, approval rate, portion of cases filed by living employee, mortality rates, medical cost and inflation rates. We also needed to assume a percentage of Part E cases where medical was not already being paid under Part B. We used 40%, the same as last year.

Exhibit 2 - Summary Medical Paid Loss Data

Averages are taken over several different groups. The average medical is selected the same for Part E as for Part B. We selected \$9,000 for both Part B and Part E, the same as last year.

Exhibit 3 - Summarized Information from our Data Base

Tables 1 through 12 show summarized information from the database.

From this data, we estimated a case approval rate and payments made by disease and year. The approval of a case required only that one underlying claim be approved, and we did not count a case as disapproved if any underlying claim was approved or reopened.

Exhibit 3, page 5 – Estimate of Part E average compensation award

The various possible types of cases and claimants are weighted to produce a single average award. Because of possible overlap in the categories, the weights used in the selection total to more than 100%.

Exhibit 4 - Estimation of Ultimate Case Count and Emergence Pattern by Disease

To calculate the ultimate number of cases reported by disease, we projected based on reported case counts from the latest 27 quarters in our database. This excluded the third quarter of 2001. We fit an exponential decay reporting pattern to the quarterly data. Using actual cases as of 6/30/08, the last complete quarter, and the fitted pattern for projection, we were able to calculate an expected ultimate number of reported cases. We selected exponential parameters that may have differed from the values resulting from the fit on the existing data usually by comparing last years projections for the current year to the actual number of claims filed and by comparing future projection with the latest reported numbers.

In addition to an estimate of an ultimate number of cases, the exponential decay model also gives us a reporting pattern, which we have used to derive a payment pattern for discounting.

Exhibit 5, page 1 - Estimated Ultimate Approved Cases by Disease

Using the selected approval rate by disease from Exhibit 1 and the number of filed claims from Exhibit 4, we calculated the expected number of cases reported by fiscal year that would be approved.

Exhibit 5, page 2 - Estimated Ultimate Paid Cases by Disease

The database gives us some information about the difference between the filing date and the approval date. For RECA and CN-SEC, we assumed payout would follow the year after the (approved) case was filed. Based on judgment, we assumed a two-year lag between filing and payment of other Part B cases. Part E cases are assumed to be paid 4 years after filing, 2 years from filing to approval and a two year duration of payments. This assumes that cases will be decided more quickly now that most of the initial backlog of claims has been handled. Further adjustments are made as described in the exhibit and in section C1 of this report.

Exhibit 5, page 3 – Cases Eligible for Medical Expenses

To be eligible for medical, claims must be approved and filed by a living employee. Once he/she becomes eligible, the claimant continues to be eligible in subsequent years, subject to mortality.

Exhibit 6 - Dollars Paid by Disease by Fiscal Year

The liability by disease is the sum of projected payments after 9/30/08, and summarized on Exhibit 1.

The projected payout of cases is used in conjunction with actual payments to date to derive the payout distribution by fiscal year, which can be used with a selected interest rate to discount the liabilities. The interest rates decreased this year compared to last year so the discounted liabilities are higher than if last years interest rate was used.

Exhibit 7 – Sensitivity Analysis

By far the most sensitive part of our analysis is the projection of ultimate emerged cases. This is especially difficult because we don't really know the true exposure to loss, which is the number of at-risk employees. Though there have been some estimates in total and maybe by occupation, what we would really like is number of employees by year of employment. As far as we know, this is not available.

Our other selections have less overall impact, but correlation of these is possible and the consequent error in our projection of these could still be quite large. Exhibit 7 shows estimates of liability with some different parameter selections to provide an idea of how much the estimate could vary if different parameters were selected.

1. An exponential decay model is reasonable if there are no exogenous factors, but with existing changes in administration such as awareness programs and the addition of new SEC classes, we see actual changes that cannot fully be modeled. For sensitivity, we tested the impact of increasing and decreasing the selected slope parameter one percentage point, 0.01. This sounds like a small change but the slope parameters are in the range .025 to .08 so .01 is a large percentage change. The increase in slope increased discounted reserves some 96%, while the decrease reduced them 24%. The model is especially sensitive to this selection.
2. The choice of Medical inflation rate can also have great impact. Our selection of 6% is higher than that selected by the Office of Management and Budget (OMB) for projecting FECA medical payments in the DOL model, but is certainly reasonable. Our tests show the impact of varying this assumption is that an 8% rate would increase total discounted reserve 10% and a 4% rate would reduce total discounted reserves 7%.
3. Change in Medical cost per case has a lesser impact on reserves so that a 10% increase in the cost per case increases total reserves only 3.4% while a 10% decrease in that cost reduces reserves by the same percentage. Our choice of medical average cost has moderate impact.
4. Approval rates have a slightly leveraged impact, so that a 10% higher approval rate increases the reserve over 15% while a 10% lower approval rate tends to reduce reserves almost 16%. The approval rates have become more stable for all diseases

except CN-NONSEC and Part E. Re-adjudication of previously denied claims has increased the uncertainty of the long term approval rate.

5. Interest rates can have great impact. We used the OMB's recommendations for long term interest rates used in the FECA reserves and see little need for judgmental adjustment. We show a one point change in interest rate can impact reserves about 7-9%.

CHANGES IN METHODOLOGY

The major changes in methodology compared to last years analysis:

- 1) We selected a slower decay rate for projecting the number of Part E claims to be filed. This resulted in a greater number of claims projected to be filed after 2035, the last year used in the projections in the 2007 analysis. Therefore, the projection period for Part E was lengthened to the year 2045. A small part of the increase in liability for Part E due to these changes was offset by selecting a lower cost per case, \$143,000 compared to \$150,000 last year.
- 2) We adjusted the assumptions as to how long it takes to pay a claim. CN-SEC cases are assumed to be paid one year after filing instead of two. Part E claims are assumed to be paid 4 years after filing instead of 5. These changes were made because it appears that claims are being paid faster now that the backlog is clearing.
- 3) The selected approval rates and decay rates for some diseases in Part B are changed based on the new data.

CAVEATS

This work is a good faith estimate of the EEOICPA liabilities. We have tried to use the actual experience as much as possible to make our estimate and also give weight to information from staff about changes in the program that are not yet seen in the data. Nevertheless, the estimate is based to a great extent on judgment. As with all such estimations of future contingent events, this one, even based on known experience, includes a significant probability of being incorrect. This risk is contained in all actuarial estimations of future costs, but is particularly high in this case.

The EEOICPA program is relatively new, with only a short history to serve as an example of possible events especially when compared to a commercial line of insurance such as Workers Compensation or Premises Liability. The EEOICPA experience so far is only a fraction of the ultimate events that will occur as this program plays out. Part E in particular has generated very little experience so we are relying heavily on judgment to produce estimates.

We relied on the data supplied by the Department of Labor to make this estimate. We examined it for consistency and reasonableness but otherwise relied on the accuracy of the information provided to us.

What actuaries call the exposure to loss - the time, place, people and what they were doing many years ago - is not measured very accurately in comparison to commercial insurance lines of business, where we would have audited payroll by year and location, and comparatively prompt notification of insured events. In this case, eligible claimants were working at several different locations during many different time periods spanning many years in the past.

Qualification for the benefits is based on a newly instituted and evolving administrative procedure, again with not much historical experience to model the process. One constant has been that for Part B, the size of the awards: a flat lump sum of \$150,000. This helps reduce possible error in the estimate. For Part E there are varying possible awards adding another source of error in the estimate.

There are three possible kinds of risk in all estimations. One is parameter risk, or the risk that our model of the process is not accurate. There are many variables that impact the results and it is possible that some of them are not estimated accurately. The parameter risk in this case is sizable.

Another is called process risk. Even if we are able to correctly model the loss process, it is, after all, stochastic, and actual events may depart from what we predict, even if what we predict is correct on average. Actuaries would call this average the true expected losses. Because the possible triggers for an award under the EEOICPA are so complex, process risk is high, and fortuitous events in the future may not follow patterns seen in the data.

The third is model risk. This is the risk that the model is not appropriate for the estimate. For example, the exponential decay model for modeling the number of claims may not be appropriate for this particular coverage.



Judy A. Gillam, FCAS, MAAA



William R. Gillam, FCAS, MAAA

**ESTIMATED LIABILITY FOR EEOIC
AS OF 9/30/2008**

Undiscounted Future Liability	Part B \$6,236,610,079	Part E \$6,829,426,204	Total \$13,066,036,283
Discounted Liability Using an interest rate of 4.770%	\$4,043,713,292	\$4,055,605,311	\$8,099,318,603

ESTIMATED PAYOUT FOR CURRENT EEOIC LIABILITY

(1) Fiscal Year	(2) Years of Discount	(3) Discount Factor	(4) PART B Undiscounted Payout	(5) = (3) x (4) PART B Discounted Payout	(6) PART E Undiscounted Payout	(7) =(3) x (6) PART E Discounted Payout
10/08-9/09	0.5	0.977	575,268,000	562,036,836	525,924,000	513,827,748
10/09-9/10	1.5	0.932	479,110,560	446,531,042	471,394,100	439,339,301
10/10-9/11	2.5	0.890	385,408,640	343,013,690	389,875,672	346,989,348
10/11-9/12	3.5	0.850	358,827,930	305,003,741	319,298,840	271,404,014
10/12-9/13	4.5	0.811	336,414,692	272,832,315	311,188,462	252,373,843
10/13-9/14	5.5	0.774	289,333,484	223,944,117	287,875,008	222,815,256
10/14-9/15	6.5	0.739	271,449,757	200,601,370	266,663,687	197,064,465
10/15-9/16	7.5	0.705	255,165,663	179,891,792	247,540,202	174,515,842
10/16-9/17	8.5	0.673	241,130,965	162,281,139	230,200,170	154,924,714
10/17-9/18	9.5	0.642	227,826,495	146,264,610	214,483,110	137,698,157
10/18-9/19	10.5	0.613	216,287,972	132,584,527	217,665,656	133,429,047
10/19-9/20	11.5	0.585	205,325,835	120,115,613	204,922,360	119,879,581
10/20-9/21	12.5	0.559	195,298,290	109,171,744	193,071,650	107,927,052
10/21-9/22	13.5	0.533	185,304,708	98,767,409	182,144,420	97,082,976
10/22-9/23	14.5	0.509	175,342,472	89,249,318	172,297,480	87,699,417
10/23-9/24	15.5	0.486	166,445,266	80,892,399	163,118,866	79,275,769
10/24-9/25	16.5	0.464	157,027,764	72,860,882	154,452,617	71,666,014
10/25-9/26	17.5	0.442	148,232,835	65,518,913	146,365,000	64,693,330
10/26-9/27	18.5	0.422	140,025,102	59,090,593	138,812,893	58,579,041
10/27-9/28	19.5	0.403	131,642,540	53,051,944	131,519,560	53,002,383
After 9/28			1,095,741,109	320,009,298	1,860,612,451	471,418,013
TOTAL			\$6,236,610,079	\$4,043,713,292	\$6,829,426,204	\$4,055,605,311

Column (4) payout is from Exhibit 6 column (9) excluding amounts paid before 9/30/08
Column (6) payout is from Exhibit 6 column (12) excluding amounts paid before 9/30/08
Column (3) is 1 divided by 1 plus the interest rate selected for discounting, raised to the power in column (2)

Inputs for Estimation of EEOIC liabilities

Exhibit 1
Page 2

Table 1

Interest Rate to use for Discounting Reserves 4.770%

Table 2

Selected rate of approval of filed claims Actual data is in Exhibit 3 Page 2 Tables 5 and 6.

RECA	95%
BD	53%
CS	18%
CN - SEC	77%
CN - NONSEC	25%
BS	56%
PART E	40%

Table 3

Selected percentage of Cases Filed by Living Employee. These cases are eligible for medical benefits.
Actual data is in Exhibit 3 Page 1 Table 2.

RECA	54%
BD	58%
CS	72%
CN - SEC	46%
CN - NONSEC	55%
BS	99%
PART E	59%

Table 4

Mortality Rates
Assumed Average Age at Filing Claim is 67

(1)	(2)	(3)
Age	Mortality Rate	= 1-(2)
67	0.054450	0.9456
68	0.056909	0.9431
69	0.059613	0.9404
70	0.062583	0.9374
71	0.065841	0.9342
72	0.069405	0.9306
73	0.073292	0.9267
74	0.077512	0.9225
75	0.082067	0.9179
76	0.086951	0.9130
77	0.092149	0.9079
78	0.097640	0.9024
79	0.103392	0.8966
80	0.109372	0.8906
81	0.115544	0.8845
82	0.121877	0.8781
83	0.128343	0.8717
84	0.134923	0.8651
85	0.141603	0.8584
86	0.148374	0.8516
87	0.155235	0.8448
88	0.162186	0.8378
89	0.169233	0.8308
90	0.183408	0.8166
91	0.199769	0.8002
92	0.216605	0.7834
93	0.233662	0.7663
94	0.250693	0.7493
95	0.267491	0.7325
96	0.283905	0.7161
97	0.299852	0.7001
98	0.315296	0.6847
99	0.330207	0.6698
100	0.344556	0.6554
101	0.358628	0.6414
102	0.371685	0.6283

Column (2) Mortality Rates are from Male RP-2000 Rates for Disabled Retiree

Table 5

Selected Part B Medical Annual Cost \$9,000
Selected Part E Medical Annual Cost \$9,000
Medical Inflation Rate = 6%

(1)	(2)	(3)
Fiscal Year		Avg. Medical Benefit
Ending		
9/09	1	9,000
9/10	2	9,540
9/11	3	10,112
9/12	4	10,719
9/13	5	11,362
9/14	6	12,044
9/15	7	12,767
9/16	8	13,533
9/17	9	14,345
9/18	10	15,205
9/19	11	16,118
9/20	12	17,085
9/21	13	18,110

Column (3) is the medical annual cost times 1 plus the medical inflation rate raised to the power in column (2) - 1
Actual data from Exhibit 2 Table 1.

Table 6

Percentage of approved E Claims filed with B Claims where Medical is not already approved and presumed being paid under the B claim

40%

ESTIMATE OF PAID MEDICAL FOR EEOIC

Exhibit 2
Page 1

Table 1

ALL PARTS B AND E

Actual Medical Paid Quarterly Per all Eligible Cases

(1)	(2)	(3)	(4)	(5)
	Cases Eligible	Cumulative	Total Medical Paid	= (4) / (3) Average
3Q 2001	51	51	-1,217,105	-23,865
4Q 2001	410	461	2,155	5
1Q 2002	378	839	302,819	361
2Q 2002	389	1,228	1,537,061	1,252
3Q 2002	413	1,641	1,980,503	1,207
4Q 2002	468	2,109	1,743,422	827
1Q 2003	400	2,509	3,438,041	1,370
2Q 2003	249	2,758	4,334,247	1,572
3Q 2003	180	2,938	5,223,285	1,778
4Q 2003	212	3,150	4,178,935	1,327
1Q 2004	248	3,398	7,171,640	2,111
2Q 2004	219	3,617	6,444,015	1,782
3Q 2004	226	3,843	5,207,753	1,355
4Q 2004	217	4,060	6,832,950	1,683
1Q 2005	251	4,311	7,931,896	1,840
2Q 2005	314	4,625	9,065,310	1,960
3Q 2005	324	4,949	8,946,991	1,808
4Q 2005	308	5,257	7,855,195	1,494
1Q 2006	375	5,632	11,330,290	2,012
2Q 2006	422	6,054	12,171,320	2,010
3Q 2006	494	6,548	10,275,437	1,569
4Q 2006	471	7,019	9,403,014	1,340
1Q 2007	638	7,657	13,410,213	1,751
2Q 2007	945	8,602	17,335,643	2,015
3Q 2007	1,122	9,724	22,316,385	2,295
4Q 2007	1,008	10,732	16,841,993	1,569
1Q 2008	904	11,636	17,805,578	1,530
2Q 2008	1,091	12,727	19,528,454	1,534
Total	12,727	138,075	231,397,440	1,676

ESTIMATE OF PAID MEDICAL FOR EEOIC

ALL PART B

Actual Medical Paid Quarterly Per all Eligible Cases

Exhibit 2
Page 2

	(1)	(2)	(3)	(4)	(5)
	Cases Eligible	Cumulative	Total	Medical Paid	= (4) / (3)
					Average
3Q 2001	51	51	-1,149,955		-22,548
4Q 2001	410	461	2,155		5
1Q 2002	378	839	302,819		361
2Q 2002	389	1,228	1,537,061		1,252
3Q 2002	413	1,641	1,979,072		1,206
4Q 2002	468	2,109	1,742,811		826
1Q 2003	400	2,509	3,413,438		1,360
2Q 2003	249	2,758	4,315,956		1,565
3Q 2003	180	2,938	5,201,712		1,770
4Q 2003	212	3,150	4,154,922		1,319
1Q 2004	248	3,398	7,144,293		2,102
2Q 2004	219	3,617	6,412,975		1,773
3Q 2004	226	3,843	5,178,359		1,347
4Q 2004	217	4,060	6,813,360		1,678
1Q 2005	251	4,311	7,907,565		1,834
2Q 2005	314	4,625	9,007,300		1,948
3Q 2005	322	4,947	8,823,823		1,784
4Q 2005	301	5,248	7,701,358		1,467
1Q 2006	360	5,608	10,710,982		1,910
2Q 2006	383	5,991	11,581,698		1,933
3Q 2006	427	6,418	9,499,127		1,480
4Q 2006	357	6,775	8,512,855		1,257
1Q 2007	428	7,203	12,277,457		1,704
2Q 2007	548	7,751	16,115,994		2,079
3Q 2007	518	8,269	20,550,958		2,485
4Q 2007	415	8,684	15,601,073		1,797
1Q 2008	396	9,080	16,214,857		1,786
2Q 2008	350	9,430	17,748,294		1,882
Total	9,430	126,942	219,302,319		1,728

ESTIMATE OF PAID MEDICAL FOR EEOIC

PART B RECA

Actual Medical Paid Quarterly Per all Eligible Cases

Exhibit 2
Page 3

	(1)	(2)	(3)	(4)	(5)
		Cases Eligible	Cumulative	Total Medical Paid	= (4) / (3) Average
3Q 2001		38	38	-220,574	-5,805
4Q 2001		297	335	799	2
1Q 2002		109	444	82,912	187
2Q 2002		82	526	85,987	163
3Q 2002		111	637	186,479	293
4Q 2002		100	737	199,246	270
1Q 2003		84	821	390,804	476
2Q 2003		51	872	729,361	836
3Q 2003		41	913	1,089,936	1,194
4Q 2003		62	975	937,224	961
1Q 2004		79	1,054	1,249,399	1,185
2Q 2004		85	1,139	1,256,344	1,103
3Q 2004		80	1,219	1,250,478	1,026
4Q 2004		51	1,270	2,798,177	2,203
1Q 2005		110	1,380	3,918,095	2,839
2Q 2005		123	1,503	4,207,377	2,799
3Q 2005		97	1,600	3,690,902	2,307
4Q 2005		81	1,681	2,417,792	1,438
1Q 2006		92	1,773	5,134,111	2,896
2Q 2006		65	1,838	4,997,513	2,719
3Q 2006		105	1,943	3,691,821	1,900
4Q 2006		79	2,022	3,066,473	1,517
1Q 2007		156	2,178	4,540,259	2,085
2Q 2007		258	2,436	6,696,575	2,749
3Q 2007		236	2,672	7,150,380	2,676
4Q 2007		145	2,817	5,630,297	1,999
1Q 2008		112	2,929	5,824,576	1,989
2Q 2008		67	2,996	6,492,747	2,167
Total		2,996	40,748	77,495,490	1,902

ESTIMATE OF PAID MEDICAL FOR EEOIC

PART B CN-SEC

Actual Medical Paid Quarterly Per all Eligible Cases

Exhibit 2
Page 4

	(1)	(2)	(3)	(4)	(5)
		Cases Eligible	Cumulative	Total Medical Paid	= (4) / (3) Average
3Q 2001		12	12	-456,274	-38,023
4Q 2001		82	94	973	10
1Q 2002		178	272	193,179	710
2Q 2002		114	386	1,411,704	3,657
3Q 2002		131	517	1,643,774	3,179
4Q 2002		103	620	1,271,487	2,051
1Q 2003		100	720	1,994,870	2,771
2Q 2003		86	806	2,276,117	2,824
3Q 2003		44	850	3,020,806	3,554
4Q 2003		53	903	2,507,091	2,776
1Q 2004		51	954	4,413,904	4,627
2Q 2004		44	998	3,823,261	3,831
3Q 2004		51	1,049	2,935,243	2,798
4Q 2004		56	1,105	2,810,901	2,544
1Q 2005		37	1,142	2,971,319	2,602
2Q 2005		54	1,196	3,219,679	2,692
3Q 2005		76	1,272	3,315,588	2,607
4Q 2005		106	1,378	3,520,986	2,555
1Q 2006		99	1,477	3,808,426	2,578
2Q 2006		107	1,584	3,916,669	2,473
3Q 2006		109	1,693	3,521,442	2,080
4Q 2006		91	1,784	3,249,424	1,821
1Q 2007		95	1,879	4,733,344	2,519
2Q 2007		94	1,973	5,883,225	2,982
3Q 2007		126	2,099	8,144,958	3,880
4Q 2007		150	2,249	6,460,594	2,873
1Q 2008		142	2,391	6,365,608	2,662
2Q 2008		132	2,523	6,543,190	2,593
Total		2,523	33,926	93,501,488	2,756

ESTIMATE OF PAID MEDICAL FOR EEOIC

PART B CN-NONSEC

Actual Medical Paid Quarterly Per all Eligible Cases

Exhibit 2
Page 5

(1)	(2)	(3)	(4)	(5)
	Cases Eligible	Cumulative	Total Medical Paid	= (4) / (3) Average
3Q 2001	0	0	-101,195	
4Q 2001	0	0	0	
1Q 2002	0	0	0	
2Q 2002	0	0	0	
3Q 2002	0	0	74	
4Q 2002	2	2	3,473	1,737
1Q 2003	1	3	15,763	5,254
2Q 2003	8	11	19,195	1,745
3Q 2003	15	26	87,549	3,367
4Q 2003	43	69	56,630	821
1Q 2004	37	106	217,223	2,049
2Q 2004	30	136	295,239	2,171
3Q 2004	33	169	240,319	1,422
4Q 2004	65	234	334,061	1,428
1Q 2005	58	292	317,946	1,089
2Q 2005	85	377	503,174	1,335
3Q 2005	109	486	610,387	1,256
4Q 2005	79	565	678,730	1,201
1Q 2006	133	698	797,361	1,142
2Q 2006	157	855	1,607,814	1,880
3Q 2006	167	1,022	1,085,292	1,062
4Q 2006	141	1,163	1,126,168	968
1Q 2007	118	1,281	1,856,470	1,449
2Q 2007	125	1,406	2,253,919	1,603
3Q 2007	77	1,483	3,463,732	2,336
4Q 2007	53	1,536	1,870,861	1,218
1Q 2008	74	1,610	2,200,511	1,367
2Q 2008	82	1,692	2,551,491	1,508
Total	1,692	15,222	22,092,187	1,451

ESTIMATE OF PAID MEDICAL FOR EEOIC

PART B BD, CS, AND BS

Actual Medical Paid Quarterly Per all Eligible Cases

Exhibit 2
Page 6

	(1)	(2)	(3)	(4)	(5)
	Cases Eligible	Cumulative	Total Medical Paid	= (4) / (3)	Average
3Q 2001	1	1	-371,912	-371,912	
4Q 2001	31	32	383	12	
1Q 2002	91	123	26,728	217	
2Q 2002	193	316	39,370	125	
3Q 2002	171	487	148,745	305	
4Q 2002	263	750	268,605	358	
1Q 2003	215	965	1,011,641	1,048	
2Q 2003	104	1,069	1,290,533	1,207	
3Q 2003	80	1,149	1,002,971	873	
4Q 2003	54	1,203	653,977	544	
1Q 2004	81	1,284	1,263,767	984	
2Q 2004	60	1,344	1,037,531	772	
3Q 2004	62	1,406	751,689	535	
4Q 2004	45	1,451	870,021	600	
1Q 2005	46	1,497	699,905	468	
2Q 2005	52	1,549	1,076,500	695	
3Q 2005	40	1,589	1,206,546	759	
4Q 2005	35	1,624	1,083,850	667	
1Q 2006	36	1,660	970,688	585	
2Q 2006	54	1,714	1,057,888	617	
3Q 2006	46	1,760	1,199,230	681	
4Q 2006	46	1,806	1,067,415	591	
1Q 2007	59	1,865	1,141,884	612	
2Q 2007	71	1,936	1,272,322	657	
3Q 2007	79	2,015	1,781,176	884	
4Q 2007	67	2,082	1,627,516	782	
1Q 2008	68	2,150	1,816,682	845	
2Q 2008	69	2,219	2,148,662	968	
Total	2,219	37,046	26,144,313	706	

**DATABASE SUMMARY INFORMATION
As of approximately 7/20/2008**

Exhibit 3
Page 1

Table 1

Number of Cases and Claims By Disease

	# Cases	# Claims
RECA	6,634	10,549
BD	3,998	6,027
CS	529	708
CN-SEC	13,944	24,213
CN-NONSEC	26,365	37,994
BS	2,138	2,155
OL	2,983	3,424
RN	451	554
OTHER	4,399	4,828
99	1,308	1,384
PA	2	2
Unknown	269	274
PART B SUBTOTAL	63,020	92,112
PART E - WITH PART B CLAIM	47,436	67,631
PART E - ONLY	5,577	6,192
PART E SUBTOTAL	53,013	73,823
Cases with no Claims	392	0
TOTAL	116,425 *	165,935

*Total number of cases includes cases double counted as Part B and Part E. The total number of cases is 68,989.

Table 2

Cases Filed by Employee or Survivors or Both.

	(1) EMP	(2) SUR	(3) BOTH	(4) Percentage EMP
RECA	3,412	3,060	162	53.9%
BD	2,067	1,697	234	57.6%
CS	351	146	32	72.4%
CN-SEC	5,194	7,491	1,259	46.3%
CN-NONSEC	12,531	11,953	1,881	54.7%
BS	2,105	27	6	98.7%
PART E	28,811	21,598	2,604	59.3%
TOTAL	54,471	45,972	6,178	56.9%

Column (4) is the sum of Columns (1) and (3) divided by sum of columns (1), (2) and (3).

Table 3

Avg. Age of Employee At Time Claim is Filed

Employee Filed Cases Only

Year of Claim Filing	Part B	Number Cases	Part E	Number Cases
2001	67	8,775	65	2,530
2002	65	7,857	65	5,216
2003	65	4,897	64	4,621
2004	67	3,954	67	3,350
2005	67	3,436	68	5,908
2006	67	2,839	67	4,012
2007	68	3,159	67	4,014
2008 *	68	1,399	67	1,760
Total	66	36,316	66	31,411

* 2008 data is for a partial year

Table 4

Sex of Employee

	Male	Female	Blank	Male Percentage
RECA	6,521	101	12	98.5%
BD	3,556	441	1	89.0%
CS	508	21	0	96.0%
CN-SEC	12,142	1,791	11	87.1%
CN-NONSEC	23,286	3,056	23	88.4%
BS	1,713	423	2	80.2%
PART E	46,241	6,434	338	87.8%
Total	93,967	12,267	387	88.5%

Table 5

Percentage of Cases Recommended Accept

	Recommend Accept	Recommend Deny	Percentage Rec Accept
RECA	5,955	340	94.6%
BD	1,849	1,892	49.4%
CS	73	405	15.3%
CN-SEC	8,515	3,075	73.5%
CN-NONSEC	4,895	14,749	24.9%
BS	1,143	927	55.2%
OL	2	2,885	0.1%
RN	0	433	0.0%
OTHER	0	4,304	0.0%
99	2	1,265	0.2%
Unknown	0	147	0.0%
PA	0	2	0.0%
SUBTOTAL EXCL F	22,434	30,424	42.4%
PART E	16,318	26,297	38.3%
TOTAL	38,752	56,721	40.6%

Table 6

Percentage of Cases FAB Accept

	FAB Accept	FAB Deny	Percent FAB Accept
	5,884	302	95.1%
	1,937	1,736	52.7%
	84	381	18.1%
	8,626	2,539	77.3%
	4,830	13,746	26.0%
	1,139	893	56.1%
	2	2,838	0.1%
	0	426	0.0%
	0	4,255	0.0%
	2	1,238	0.2%
	0	146	0.0%
	0	2	0.0%
	22,504	28,502	44.1%
	16,055	24,437	39.6%
	38,559	52,939	42.1%

Table 7

Report Qtr Actual Cases Filed By Report Quarter

Report Qtr	PART B										Blank	Subtotal	PART E	TOTAL
	RECA	BD	CS	CN-SEC	CN-NONSEC	BS	OL	RN	OTHER	99				
No Date	2	0	0	1	8	0	0	0	3	0	2	16	5	21
3Q 2001	1,532	820	123	2,092	3,775	198	543	91	679	167	52	10,072	2144	12,216
4Q 2001	346	342	75	918	2,962	114	452	78	509	146	48	5,990	2052	8,042
1Q 2002	278	335	42	957	2,428	146	360	62	483	153	36	5,280	2810	8,090
2Q 2002	246	249	20	726	1,438	194	260	41	411	103	49	3,737	2403	6,140
3Q 2002	201	138	17	634	1,062	153	194	34	266	91	38	2,828	2055	4,883
4Q 2002	154	163	18	432	827	94	133	26	207	48	12	2,114	1715	3,829
1Q 2003	106	131	6	476	878	86	136	21	206	46	0	2,092	1600	3,692
2Q 2003	133	126	10	426	877	92	158	17	325	116	2	2,282	2159	4,441
3Q 2003	120	148	14	369	802	71	77	10	139	40	1	1,791	2046	3,837
4Q 2003	156	152	9	390	819	52	66	10	131	40	0	1,825	1823	3,648
1Q 2004	195	201	16	474	939	49	52	7	133	42	1	2,109	1846	3,955
2Q 2004	121	174	7	386	712	45	37	5	87	25	0	1,599	1143	2,742
3Q 2004	139	206	21	483	788	119	48	7	117	22	0	1,950	1336	3,286
4Q 2004	156	92	12	334	541	33	52	5	93	29	0	1,347	1767	3,114
1Q 2005	213	126	14	383	733	57	75	4	82	46	2	1,735	2913	4,648
2Q 2005	273	95	13	390	723	55	53	6	54	16	2	1,680	3683	5,363
3Q 2005	220	77	9	312	616	47	19	2	66	18	2	1,388	2281	3,669
4Q 2005	164	36	8	337	465	28	17	2	25	6	2	1,090	1797	2,887
1Q 2006	185	42	11	322	490	26	17	1	22	6	1	1,123	1710	2,833
2Q 2006	144	34	5	317	443	47	18	1	24	8	5	1,046	1486	2,532
3Q 2006	309	42	8	304	462	44	24	1	23	9	0	1,226	1590	2,816
4Q 2006	229	39	15	320	454	74	31	0	41	20	5	1,228	1641	2,869
1Q 2007	229	48	10	380	746	71	41	2	66	22	0	1,615	2060	3,675
2Q 2007	185	42	7	331	469	42	12	2	32	15	2	1,139	1429	2,568
3Q 2007	122	53	10	355	514	64	12	2	28	11	2	1,173	1432	2,605
4Q 2007	150	36	12	365	494	42	48	3	82	27	1	1,260	1342	2,602
1Q 2008	160	20	9	328	386	46	27	6	40	19	3	1,044	1210	2,254
2Q 2008	151	26	7	363	435	43	20	5	23	16	1	1,090	1360	2,450
3Q 2008	15	5	1	39	79	6	1	0	2	1	0	149	175	324
Total	6,634	3,998	529	13,944	26,365	2,138	2,983	451	4,399	1,308	269	63,018	53,013	116,031

*Third quarter 2008 data is for an incomplete quarter.

DATABASE SUMMARY INFORMATION
As of approximately 7/20/2008

Exhibit 3
Page 4

Table 11

Paid Qtr	Medical Actual Dollars Paid By Quarter												
	RECA	BD	CS	CN-SEC	CN-NONSEC	BS	OL	RN	OTHER	99	Blank	Part E	TOTAL
3Q 2001	-220,574	-317,491	-22,328	-456,274	-101,195	-32,093	0	0	0	0	0	-67,150	-1,217,105
4Q 2001	0	0	0	0	0	0	0	0	0	0	0	0	0
1Q 2002	799	0	383	973	0	0	0	0	0	0	0	0	2,155
2Q 2002	82,912	1,844	24,884	193,179	0	0	0	0	0	0	0	0	302,819
3Q 2002	85,987	29,790	9,075	1,411,704	0	505	0	0	0	0	0	0	1,537,061
4Q 2002	186,479	136,863	5,597	1,643,774	74	6,285	0	0	0	0	0	1,431	1,980,503
1Q 2003	199,246	229,893	13,193	1,271,487	3,473	25,519	0	0	0	0	0	611	1,743,422
2Q 2003	390,804	861,298	7,512	1,994,870	15,763	142,831	0	0	360	0	0	24,603	3,438,041
3Q 2003	729,361	1,055,175	19,728	2,276,117	19,195	215,630	750	0	0	0	0	18,291	4,334,247
4Q 2003	1,089,936	784,329	18,604	3,020,806	87,549	200,038	0	0	450	0	0	21,573	5,223,285
1Q 2004	937,224	484,707	40,580	2,507,091	56,630	128,690	0	0	0	0	0	24,013	4,178,935
2Q 2004	1,249,399	975,460	34,993	4,413,904	217,223	253,314	0	0	0	0	0	27,347	7,171,640
3Q 2004	1,256,344	798,771	47,086	3,823,261	295,239	191,674	0	0	0	600	0	31,040	6,444,015
4Q 2004	1,250,478	609,806	22,607	2,935,243	240,319	119,276	0	0	630	0	0	29,394	5,207,753
1Q 2005	2,798,177	738,372	30,154	2,810,901	334,061	101,495	0	0	0	200	0	19,590	6,832,950
2Q 2005	3,918,095	568,655	43,557	2,971,319	317,946	87,693	0	0	300	0	0	24,331	7,931,896
3Q 2005	4,207,377	881,941	28,267	3,219,679	503,174	166,292	0	0	570	0	0	58,010	9,065,310
4Q 2005	3,690,902	1,002,269	48,468	3,315,588	610,387	155,809	400	0	0	0	0	123,168	8,946,991
1Q 2006	2,417,792	842,003	72,963	3,520,986	678,730	168,884	0	0	0	0	0	153,837	7,855,195
2Q 2006	5,134,111	797,579	75,704	3,808,426	797,361	97,405	146	0	250	0	0	619,308	11,330,290
3Q 2006	4,997,513	837,195	105,020	3,916,669	1,607,814	115,673	0	0	1,814	0	0	589,622	12,171,320
4Q 2006	3,691,821	1,006,121	72,520	3,521,442	1,085,292	120,589	0	0	967	0	375	776,310	10,275,437
1Q 2007	3,066,473	868,675	61,032	3,249,424	1,126,168	137,708	1,050	0	0	0	2,325	890,159	9,405,014
2Q 2007	4,540,259	979,227	69,546	4,733,344	1,856,470	93,111	2,850	0	2,650	0	0	1,132,756	13,410,213
3Q 2007	6,696,575	1,062,982	77,464	5,883,225	2,253,919	131,876	4,987	0	4,516	450	0	1,219,649	17,335,643
4Q 2007	7,150,380	1,404,779	102,572	8,144,958	3,463,732	273,825	4,512	0	5,300	900	0	1,765,427	22,316,385
1Q 2008	5,630,297	1,295,783	107,524	6,460,594	1,870,861	224,209	6,828	0	4,977	0	0	1,240,920	16,841,993
2Q 2008	5,824,576	1,453,561	106,085	6,365,608	2,200,511	257,036	4,917	0	2,563	0	0	1,590,721	17,805,578
3Q 2008	6,492,747	1,905,069	86,126	6,543,190	2,551,491	157,467	9,169	0	3,035	0	0	1,780,160	19,528,454
Medical Paid as of 7/2008	79,316,116	21,637,219	1,348,558	94,850,322	22,664,201	3,560,971	41,253	0	28,596	2,150	3,675	12,467,898	235,920,959

Table 12

Paid Qtr	Number of Cases Paid Medical By Quarter												
	RECA	BD	CS	CN-SEC	CN-NONSEC	BS	OL	RN	OTHER	99	Blank	Part E	TOTAL
No Date	362	251	16	393	142	51	0	0	0	0	0	69	1,284
3Q 2001	0	0	0	0	0	0	0	0	0	0	0	0	0
4Q 2001	3	0	1	4	0	0	0	0	0	0	0	0	8
1Q 2002	24	5	2	35	0	0	0	0	0	0	0	0	66
2Q 2002	42	25	3	75	0	1	0	0	0	0	0	0	146
3Q 2002	57	78	4	137	3	7	0	0	0	0	0	6	292
4Q 2002	68	80	6	171	4	24	0	0	0	0	0	3	356
1Q 2003	118	188	7	261	15	49	0	0	1	0	0	26	665
2Q 2003	169	245	9	328	15	68	1	0	0	0	0	19	854
3Q 2003	216	273	13	379	21	75	0	0	1	0	0	20	998
4Q 2003	260	279	12	373	16	77	0	0	0	0	0	19	1,036
1Q 2004	275	342	12	455	47	94	0	0	0	0	0	38	1,263
2Q 2004	289	368	10	478	66	91	0	0	0	1	0	47	1,350
3Q 2004	317	390	11	494	82	79	0	0	1	0	0	69	1,443
4Q 2004	375	365	13	494	76	73	0	0	0	1	0	40	1,437
1Q 2005	416	405	13	539	112	76	0	0	1	0	0	52	1,614
2Q 2005	511	443	12	593	136	109	0	0	2	0	0	55	1,861
3Q 2005	542	450	17	599	179	127	1	0	0	0	0	99	2,014
4Q 2005	611	445	21	643	198	113	0	0	0	0	0	106	2,137
1Q 2006	644	445	24	688	235	82	1	0	1	0	0	131	2,251
2Q 2006	684	527	29	841	383	100	0	0	2	0	0	424	2,990
3Q 2006	706	496	28	859	497	110	0	0	2	0	1	749	3,448
4Q 2006	750	484	29	846	503	110	1	0	0	0	2	727	3,452
1Q 2007	779	494	28	896	530	97	2	0	2	0	0	761	3,589
2Q 2007	981	548	35	1,050	645	132	6	0	4	1	0	882	4,284
3Q 2007	1,309	594	37	1,236	819	178	6	0	3	1	0	1,254	5,437
4Q 2007	1,140	543	37	1,062	717	166	7	0	5	0	0	948	4,625
1Q 2008	1,117	515	38	1,097	693	189	5	0	4	0	0	973	4,631
2Q 2008	1,182	523	35	1,193	822	149	5	0	3	0	0	1,131	5,043
3Q 2008	623	308	18	593	340	52	7	0	1	0	1	441	2,384
Medical Cases Paid as of 7/2008	14,570	10,109	520	16,812	7,296	2,479	42	0	33	4	4	9,089	60,958

Cases are counted in every quarter with a medical payment so they may be counted multiple times

Note: Medical payments are coded to case and therefore cannot be allocated between Parts B and E. Medical is counted as Part E only if there is no Part B claim or if the Part B claim is denied and the Part E claim is approved.

*Third quarter 2008 data is for an incomplete quarter.

Estimation of Part E Average Cost Per case

Benefits Paid to Employee

Impairment Benefits

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than Or Equal To			
0	50,000	1228	31,687,543	25,804
50,000	100,000	903	65,884,035	72,961
100,000	150,000	626	78,690,249	125,703
150,000	200,000	332	58,492,656	176,183
200,000	250,000	220	50,322,696	228,740
Total		3309	285,077,179	86,152

Lump Sums

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than Or Equal To			
0	50,000	2	75,000	37,500
50,000	100,000	1	72,500	72,500
100,000	150,000	2	257,500	128,750
150,000	200,000	0	0	
200,000	250,000	1	207,500	207,500
Total		6	612,500	102,083

Wage Loss Benefits

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than Or Equal To			
0	50,000	67	1,894,200	28,272
50,000	100,000	54	3,888,546	72,010
100,000	150,000	37	4,650,646	125,693
150,000	200,000	12	2,061,590	171,799
200,000	250,000	13	3,051,485	234,730
Total		183	15,546,467	84,953

Additional wage loss benefits may be paid to employees below the normal retirement age.

Total Employee Benefit

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than Or Equal To			
0	50,000	1,223	31,524,061	25,776
50,000	100,000	881	64,140,727	72,804
100,000	150,000	616	77,382,914	125,622
150,000	200,000	339	59,907,457	176,718
200,000	250,000	294	68,280,839	232,248
Total		3,353	301,235,998	89,841

Maximum Total Benefit, excluding medical, for impairment, wage loss and survivorship is \$250,000.

Benefits Paid to Survivor

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than Or Equal To			
0	50,000	51	1,503,187	29,474
50,000	100,000	134	9,705,293	72,428
100,000	150,000	6,532	831,552,238	127,304
150,000	200,000	293	51,216,919	174,802
200,000	250,000	2	480,000	240,000
Total		7,012	894,457,637	127,561

Selection of Average Part E Benefit

Employee	59%	\$90,000
Survivor	71%	\$128,000
Average		\$143,000

Selected \$143,000

Assumes 50% of employees that have received awards will die from covered condition and have eligible survivor to receive award.

The employee benefit is selected based on payments to date. Some employees will receive additional wage loss payments but also some claims are accepted for medical payments only with no impairment.

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR RECA CASES**

Exhibit 4

Parameters for fitted curve
m -0.0054 5.2656 b

Selected Parameters for
m -0.0350 6.0000 b

CASES BY QUARTER

Quarter Filed	Year	(1) t	(2) Number of Cases	(3) Actual	(4) Judgmental Adjustment	(5) y	(6) ln(y) = (3) + (5)	(7) Selected Approval Rate	(8) Approval Rate	(9) Estimated Approved Cases =(4) x (8)	(10) Case Amount	(11) Estimated Ultimate Compensation =(9) x (10)	(12) Approved Cases By Fiscal Year
3	2001		1,534	Actual	0	1534	7.33563	0.95	1457	50,000	72,850,000	1,457	
4	2001	1	346	Actual	0	346	5.84644	0.95	329	50,000	16,450,000	0	
1	2002	2	278	Actual	0	278	5.62762	0.95	264	50,000	13,200,000	0	
2	2002	3	246	Actual	0	246	5.50533	0.95	234	50,000	11,700,000	0	
3	2002	4	201	Actual	0	201	5.30330	0.95	191	50,000	9,550,000	1,018	
4	2002	5	154	Actual	0	154	5.03695	0.95	146	50,000	7,300,000	0	
1	2003	6	106	Actual	0	106	4.66344	0.95	101	50,000	5,050,000	0	
2	2003	7	133	Actual	0	133	4.89035	0.95	126	50,000	6,300,000	0	
3	2003	8	120	Actual	0	120	4.78749	0.95	114	50,000	5,700,000	487	
4	2003	9	156	Actual	0	156	5.04986	0.95	148	50,000	7,400,000	0	
1	2004	10	195	Actual	0	195	5.27300	0.95	185	50,000	9,250,000	0	
2	2004	11	121	Actual	0	121	4.79579	0.95	115	50,000	5,750,000	0	
3	2004	12	139	Actual	0	139	4.93447	0.95	132	50,000	6,600,000	580	
4	2004	13	156	Actual	0	156	5.04986	0.95	148	50,000	7,400,000	0	
1	2005	14	213	Actual	0	213	5.36129	0.95	202	50,000	10,100,000	0	
2	2005	15	273	Actual	0	273	5.60947	0.95	259	50,000	12,950,000	0	
3	2005	16	220	Actual	0	220	5.39363	0.95	209	50,000	10,450,000	818	
4	2005	17	164	Actual	0	164	5.09987	0.95	156	100,000	15,600,000	0	
1	2006	18	185	Actual	0	185	5.22036	0.95	176	100,000	17,600,000	0	
2	2006	19	144	Actual	0	144	4.96981	0.95	137	100,000	13,700,000	0	
3	2006	20	309	Actual	0	309	5.73334	0.95	294	150,000	44,100,000	763	
4	2006	21	229	Actual	0	229	5.43372	0.95	218	150,000	32,700,000	0	
1	2007	22	229	Actual	0	229	5.43372	0.95	218	150,000	32,700,000	0	
2	2007	23	185	Actual	0	185	5.22036	0.95	176	150,000	26,400,000	0	
3	2007	24	122	Actual	0	122	4.80402	0.95	116	150,000	17,400,000	728	
4	2007	25	150	Actual	0	150	5.01064	0.95	143	150,000	21,450,000	0	
1	2008	26	160	Actual	0	160	5.07517	0.95	152	150,000	22,800,000	0	
2	2008	27	151	Actual	0	151	5.01728	0.95	143	150,000	21,450,000	0	
3	2008	28	151	Projected				0.95	143	150,000	21,450,000	581	
4	2008	29	146	Projected				0.95	139	150,000	20,850,000	0	
1	2009	30	141	Projected				0.95	134	150,000	20,100,000	0	
2	2009	31	136	Projected				0.95	129	150,000	19,350,000	0	
3	2009	32	132	Projected				0.95	125	150,000	18,750,000	527	
4	2009	33	127	Projected				0.95	121	150,000	18,150,000	0	
1	2010	34	123	Projected				0.95	117	150,000	17,550,000	0	
2	2010	35	119	Projected				0.95	113	150,000	16,950,000	0	
3	2010	36	114	Projected				0.95	108	150,000	16,200,000	459	
4	2010	37	110	Projected				0.95	105	150,000	15,750,000	0	
1	2011	38	107	Projected				0.95	102	150,000	15,300,000	0	
2	2011	39	103	Projected				0.95	98	150,000	14,700,000	0	
3	2011	40	99	Projected				0.95	94	150,000	14,100,000	399	
4	2011	41	96	Projected				0.95	91	150,000	13,650,000	0	
1	2012	42	93	Projected				0.95	88	150,000	13,200,000	0	
2	2012	43	90	Projected				0.95	86	150,000	12,900,000	0	
3	2012	44	86	Projected				0.95	82	150,000	12,300,000	347	
4	2012	45	84	Projected				0.95	80	150,000	12,000,000	0	
1	2013	46	81	Projected				0.95	77	150,000	11,550,000	0	
2	2013	47	78	Projected				0.95	74	150,000	11,100,000	0	
3	2013	48	75	Projected				0.95	71	150,000	10,650,000	302	
4	2013	49	73	Projected				0.95	69	150,000	10,350,000	0	
1	2014	50	70	Projected				0.95	67	150,000	10,050,000	0	
2	2014	51	68	Projected				0.95	65	150,000	9,750,000	0	
3	2014	52	65	Projected				0.95	62	150,000	9,300,000	263	
4	2014	53	63	Projected				0.95	60	150,000	9,000,000	0	
1	2015	54	61	Projected				0.95	58	150,000	8,700,000	0	
2	2015	55	59	Projected				0.95	56	150,000	8,400,000	0	
3	2015	56	57	Projected				0.95	54	150,000	8,100,000	228	
4	2015	57	55	Projected				0.95	52	150,000	7,800,000	0	
1	2016	58	53	Projected				0.95	50	150,000	7,500,000	0	
2	2016	59	51	Projected				0.95	48	150,000	7,200,000	0	
3	2016	60	49	Projected				0.95	47	150,000	7,050,000	197	
4	2016	61	48	Projected				0.95	46	150,000	6,900,000	0	
1	2017	62	46	Projected				0.95	44	150,000	6,600,000	0	
2	2017	63	44	Projected				0.95	42	150,000	6,300,000	0	
3	2017	64	43	Projected				0.95	41	150,000	6,150,000	173	
4	2017	65	41	Projected				0.95	39	150,000	5,850,000	0	
1	2018	66	40	Projected				0.95	38	150,000	5,700,000	0	
2	2018	67	39	Projected				0.95	37	150,000	5,550,000	0	
3	2018	68	37	Projected				0.95	35	150,000	5,250,000	149	
4	2018	69	36	Projected				0.95	34	150,000	5,100,000	0	
1	2019	70	35	Projected				0.95	33	150,000	4,950,000	0	
2	2019	71	34	Projected				0.95	32	150,000	4,800,000	0	
3	2019	72	32	Projected				0.95	30	150,000	4,500,000	129	
4	2019	73	31	Projected				0.95	29	150,000	4,350,000	0	
1	2020	74	30	Projected				0.95	29	150,000	4,350,000	0	
2	2020	75	29	Projected				0.95	28	150,000	4,200,000	0	
3	2020	76	28	Projected				0.95	27	150,000	4,050,000	113	
4	2020	77	27	Projected				0.95	26	150,000	3,900,000	0	
1	2021	78	26	Projected				0.95	25	150,000	3,750,000	0	
2	2021	79	25	Projected				0.95	24	150,000	3,600,000	0	
3	2021	80	25	Projected				0.95	24	150,000	3,600,000	99	
4	2021	81	24	Projected				0.95	23	150,000	3,450,000	0	

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR RECA CASES**

Exhibit 4

Parameters for fitted curve
m -0.0054 5.2656 b

Selected Parameters for
m -0.0350 6.0000 b

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
						= (3) + (5)			=(4) x (8)		=(9) x (10)	
Quarter Filed	Year	t	Number of Cases	Judgmental Adjustment	y	In(y)	Selected Approval Rate	Estimated Approved Cases	Case Amount	Estimated Ultimate Compensation	Approved Cases By Fiscal Year	
1	2022	82	23 Projected				0.95	22	150,000	3,300,000	0	
2	2022	83	22 Projected				0.95	21	150,000	3,150,000	0	
3	2022	84	21 Projected				0.95	20	150,000	3,000,000	86	
4	2022	85	21 Projected				0.95	20	150,000	3,000,000	0	
1	2023	86	20 Projected				0.95	19	150,000	2,850,000	0	
2	2023	87	19 Projected				0.95	18	150,000	2,700,000	0	
3	2023	88	19 Projected				0.95	18	150,000	2,700,000	75	
4	2023	89	18 Projected				0.95	17	150,000	2,550,000	0	
1	2024	90	17 Projected				0.95	16	150,000	2,400,000	0	
2	2024	91	17 Projected				0.95	16	150,000	2,400,000	0	
3	2024	92	16 Projected				0.95	15	150,000	2,250,000	64	
4	2024	93	16 Projected				0.95	15	150,000	2,250,000	0	
1	2025	94	15 Projected				0.95	14	150,000	2,100,000	0	
2	2025	95	15 Projected				0.95	14	150,000	2,100,000	0	
3	2025	96	14 Projected				0.95	13	150,000	1,950,000	56	
4	2025	97	14 Projected				0.95	13	150,000	1,950,000	0	
1	2026	98	13 Projected				0.95	12	150,000	1,800,000	0	
2	2026	99	13 Projected				0.95	12	150,000	1,800,000	0	
3	2026	100	12 Projected				0.95	11	150,000	1,650,000	48	
4	2026	101	12 Projected				0.95	11	150,000	1,650,000	0	
1	2027	102	11 Projected				0.95	10	150,000	1,500,000	0	
2	2027	103	11 Projected				0.95	10	150,000	1,500,000	0	
3	2027	104	11 Projected				0.95	10	150,000	1,500,000	41	
4	2027	105	10 Projected				0.95	10	150,000	1,500,000	0	
1	2028	106	10 Projected				0.95	10	150,000	1,500,000	0	
2	2028	107	10 Projected				0.95	10	150,000	1,500,000	0	
3	2028	108	9 Projected				0.95	9	150,000	1,350,000	39	
4	2028	109	9 Projected				0.95	9	150,000	1,350,000	0	
1	2029	110	9 Projected				0.95	9	150,000	1,350,000	0	
2	2029	111	8 Projected				0.95	8	150,000	1,200,000	0	
3	2029	112	8 Projected				0.95	8	150,000	1,200,000	34	
4	2029	113	8 Projected				0.95	8	150,000	1,200,000	0	
1	2030	114	7 Projected				0.95	7	150,000	1,050,000	0	
2	2030	115	7 Projected				0.95	7	150,000	1,050,000	0	
3	2030	116	7 Projected				0.95	7	150,000	1,050,000	29	
			10,826					10,289		1,083,900,000	10,289	

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve
 Column (8) is from Exhibit 1 Page 2 Table 2
 Column (12) is the sum of column (9) for rows in the fiscal year

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR BERYLLIUM DISEASE CASES**

Exhibit 4

Parameters for fitted curve
m -0.0944 5.7890 b

Parameters Selected for
m -0.0800 5.4000 b

CASES BY QUARTER

Quarter Filed	Year	(3) Number of Cases	(4)	(5) Judgmental Adjustment	(6)	(7)	(8)	(9)	(10)	(11)	(12)
					= (3) + (5)	ln(y)	Selected Approval Rate	Approved Cases	Case Amount	Estimated Ultimate Compensation	Approved Cases By Fiscal Year
3	2001	820 Actual	0	820	6.70930	0.53	435	150,000	65,250,000	435	
4	2001	342 Actual	0	342	5.83481	0.53	181	150,000	27,150,000	0	
1	2002	335 Actual	0	335	5.81413	0.53	178	150,000	26,700,000	0	
2	2002	249 Actual	0	249	5.51745	0.53	132	150,000	19,800,000	0	
3	2002	138 Actual	0	138	4.92725	0.53	73	150,000	10,950,000	564	
4	2002	163 Actual	0	163	5.09375	0.53	86	150,000	12,900,000	0	
1	2003	131 Actual	0	131	4.87520	0.53	69	150,000	10,350,000	0	
2	2003	126 Actual	0	126	4.83628	0.53	67	150,000	10,050,000	0	
3	2003	148 Actual	0	148	4.99721	0.53	78	150,000	11,700,000	300	
4	2003	152 Actual	0	152	5.02388	0.53	81	150,000	12,150,000	0	
1	2004	201 Actual	0	201	5.30330	0.53	107	150,000	16,050,000	0	
2	2004	174 Actual	0	174	5.15906	0.53	92	150,000	13,800,000	0	
3	2004	206 Actual	0	206	5.32788	0.53	109	150,000	16,350,000	389	
4	2004	92 Actual	0	92	4.52179	0.53	49	150,000	7,350,000	0	
1	2005	126 Actual	0	126	4.83628	0.53	67	150,000	10,050,000	0	
2	2005	95 Actual	0	95	4.55388	0.53	50	150,000	7,500,000	0	
3	2005	77 Actual	0	77	4.34381	0.53	41	150,000	6,150,000	207	
4	2005	36 Actual	0	36	3.58352	0.53	19	150,000	2,850,000	0	
1	2006	42 Actual	0	42	3.73767	0.53	22	150,000	3,300,000	0	
2	2006	34 Actual	0	34	3.52636	0.53	18	150,000	2,700,000	0	
3	2006	42 Actual	0	42	3.73767	0.53	22	150,000	3,300,000	81	
4	2006	39 Actual	0	39	3.66356	0.53	21	150,000	3,150,000	0	
1	2007	48 Actual	0	48	3.87120	0.53	25	150,000	3,750,000	0	
2	2007	42 Actual	0	42	3.73767	0.53	22	150,000	3,300,000	0	
3	2007	53 Actual	0	53	3.97029	0.53	28	150,000	4,200,000	96	
4	2007	36 Actual	0	36	3.58352	0.53	19	150,000	2,850,000	0	
1	2008	20 Actual	0	20	2.99573	0.53	11	150,000	1,650,000	0	
2	2008	26 Actual	0	26	3.25810	0.53	14	150,000	2,100,000	0	
3	2008	24 Projected				0.53	13	150,000	1,950,000	57	
4	2008	22 Projected				0.53	12	150,000	1,800,000	0	
1	2009	20 Projected				0.53	11	150,000	1,650,000	0	
2	2009	19 Projected				0.53	10	150,000	1,500,000	0	
3	2009	17 Projected				0.53	9	150,000	1,350,000	42	
4	2009	16 Projected				0.53	8	150,000	1,200,000	0	
1	2010	15 Projected				0.53	8	150,000	1,200,000	0	
2	2010	13 Projected				0.53	7	150,000	1,050,000	0	
3	2010	12 Projected				0.53	6	150,000	900,000	29	
4	2010	11 Projected				0.53	6	150,000	900,000	0	
1	2011	11 Projected				0.53	6	150,000	900,000	0	
2	2011	10 Projected				0.53	5	150,000	750,000	0	
3	2011	9 Projected				0.53	5	150,000	750,000	22	
4	2011	8 Projected				0.53	4	150,000	600,000	0	
1	2012	8 Projected				0.53	4	150,000	600,000	0	
2	2012	7 Projected				0.53	4	150,000	600,000	0	
3	2012	7 Projected				0.53	4	150,000	600,000	16	
4	2012	6 Projected				0.53	3	150,000	450,000	0	
1	2013	6 Projected				0.53	3	150,000	450,000	0	
2	2013	5 Projected				0.53	3	150,000	450,000	0	
3	2013	5 Projected				0.53	3	150,000	450,000	12	
4	2013	4 Projected				0.53	2	150,000	300,000	0	
1	2014	4 Projected				0.53	2	150,000	300,000	0	
2	2014	4 Projected				0.53	2	150,000	300,000	0	
3	2014	3 Projected				0.53	2	150,000	300,000	8	
4	2014	3 Projected				0.53	2	150,000	300,000	0	
1	2015	3 Projected				0.53	2	150,000	300,000	0	
2	2015	3 Projected				0.53	2	150,000	300,000	0	
3	2015	3 Projected				0.53	2	150,000	300,000	8	
4	2015	2 Projected				0.53	1	150,000	150,000	0	
1	2016	2 Projected				0.53	1	150,000	150,000	0	
2	2016	2 Projected				0.53	1	150,000	150,000	0	
3	2016	2 Projected				0.53	1	150,000	150,000	4	
4	2016	2 Projected				0.53	1	150,000	150,000	0	
1	2017	2 Projected				0.53	1	150,000	150,000	0	
2	2017	1 Projected				0.53	1	150,000	150,000	0	
3	2017	1 Projected				0.53	1	150,000	150,000	4	
4	2017	1 Projected				0.53	1	150,000	150,000	0	
1	2018	1 Projected				0.53	1	150,000	150,000	0	
2	2018	1 Projected				0.53	1	150,000	150,000	0	
3	2018	1 Projected				0.53	1	150,000	150,000	4	
4	2018	1 Projected				0.53	1	150,000	150,000	0	
1	2019	1 Projected				0.53	1	150,000	150,000	0	
2	2019	1 Projected				0.53	1	150,000	150,000	0	

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR BERYLLIUM DISEASE CASES**

Exhibit 4

Parameters for fitted curve
m -0.0944 5.7890 b

Parameters Selected for
m -0.0800 5.4000 b

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12)
Quarter Filed	Year	Number of t Cases	Judgmental Adjustment	y	ln(y)	Selected Approval Rate	Approved Cases	Case Amount	Estimated Ultimate Compensation	Approved Cases By Fiscal Year		
3	2019	72	1 Projected			0.53	1	150,000	150,000	4		
4	2019	73	1 Projected			0.53	1	150,000	150,000	0		
1	2020	74	1 Projected			0.53	1	150,000	150,000	0		
2	2020	75	1 Projected			0.53	1	150,000	150,000	0		
3	2020	76	1 Projected			0.53	1	150,000	150,000	4		
4	2020	77	0 Projected			0.53	0	150,000	0	0		
1	2021	78	0 Projected			0.53	0	150,000	0	0		
2	2021	79	0 Projected			0.53	0	150,000	0	0		
3	2021	80	0 Projected			0.53	0	150,000	0	0		
4	2021	81	0 Projected			0.53	0	150,000	0	0		
1	2022	82	0 Projected			0.53	0	150,000	0	0		
2	2022	83	0 Projected			0.53	0	150,000	0	0		
3	2022	84	0 Projected			0.53	0	150,000	0	0		
4	2022	85	0 Projected			0.53	0	150,000	0	0		
1	2023	86	0 Projected			0.53	0	150,000	0	0		
2	2023	87	0 Projected			0.53	0	150,000	0	0		
3	2023	88	0 Projected			0.53	0	150,000	0	0		
4	2023	89	0 Projected			0.53	0	150,000	0	0		
1	2024	90	0 Projected			0.53	0	150,000	0	0		
2	2024	91	0 Projected			0.53	0	150,000	0	0		
3	2024	92	0 Projected			0.53	0	150,000	0	0		
4	2024	93	0 Projected			0.53	0	150,000	0	0		
1	2025	94	0 Projected			0.53	0	150,000	0	0		
2	2025	95	0 Projected			0.53	0	150,000	0	0		
3	2025	96	0 Projected			0.53	0	150,000	0	0		
4	2025	97	0 Projected			0.53	0	150,000	0	0		
1	2026	98	0 Projected			0.53	0	150,000	0	0		
2	2026	99	0 Projected			0.53	0	150,000	0	0		
3	2026	100	0 Projected			0.53	0	150,000	0	0		
4	2026	101	0 Projected			0.53	0	150,000	0	0		
1	2027	102	0 Projected			0.53	0	150,000	0	0		
2	2027	103	0 Projected			0.53	0	150,000	0	0		
3	2027	104	0 Projected			0.53	0	150,000	0	0		
4	2027	105	0 Projected			0.53	0	150,000	0	0		
1	2028	106	0 Projected			0.53	0	150,000	0	0		
2	2028	107	0 Projected			0.53	0	150,000	0	0		
3	2028	108	0 Projected			0.53	0	150,000	0	0		
4	2028	109	0 Projected			0.53	0	150,000	0	0		
1	2029	110	0 Projected			0.53	0	150,000	0	0		
2	2029	111	0 Projected			0.53	0	150,000	0	0		
3	2029	112	0 Projected			0.53	0	150,000	0	0		
4	2029	113	0 Projected			0.53	0	150,000	0	0		
1	2030	114	0 Projected			0.53	0	150,000	0	0		
2	2030	115	0 Projected			0.53	0	150,000	0	0		
3	2030	116	0 Projected			0.53	0	150,000	0	0		
		4,297						2,286	342,900,000	2,286		

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve
 Column (8) is from Exhibit 1 Page 2 Table 2
 Column (12) is the sum of column (9) for rows in the fiscal year

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR CHRONIC SILICOSIS CASES**

Exhibit 4

Parameters for fitted curve
m -0.0432 3.1019 b

Parameters Selected for
m -0.0450 3.2000 b

CASES BY QUARTER

Quarter Filed	Year	(1) t	(2) Number of Cases	(3) Judgmental Adjustment	(4) y	(5) ln(y)	(6) Selected Approval Rate	(7) -8.00	(8) Approved Cases	(9) Case Amount	(10) Estimated Ultimate Compensation	(11) Approved Cases By Fiscal Year
3	2001		123 Actual	0	123	4.81218	0.18		22	150,000	3,300,000	22
4	2001	1	75 Actual	0	75	4.31749	0.18		14	150,000	2,100,000	0
1	2002	2	42 Actual	0	42	3.73767	0.18		8	150,000	1,200,000	0
2	2002	3	20 Actual	0	20	2.99573	0.18		4	150,000	600,000	0
3	2002	4	17 Actual	0	17	2.83321	0.18		3	150,000	450,000	29
4	2002	5	18 Actual	0	18	2.89037	0.18		3	150,000	450,000	0
1	2003	6	6 Actual	0	6	1.79176	0.18		1	150,000	150,000	0
2	2003	7	10 Actual	0	10	2.30259	0.18		2	150,000	300,000	0
3	2003	8	14 Actual	0	14	2.63906	0.18		3	150,000	450,000	9
4	2003	9	9 Actual	0	9	2.19722	0.18		2	150,000	300,000	0
1	2004	10	16 Actual	0	16	2.77259	0.18		3	150,000	450,000	0
2	2004	11	7 Actual	0	7	1.94591	0.18		1	150,000	150,000	0
3	2004	12	21 Actual	0	21	3.04452	0.18		4	150,000	600,000	10
4	2004	13	12 Actual	0	12	2.48491	0.18		2	150,000	300,000	0
1	2005	14	14 Actual	0	14	2.63906	0.18		3	150,000	450,000	0
2	2005	15	13 Actual	0	13	2.56495	0.18		2	150,000	300,000	0
3	2005	16	9 Actual	0	9	2.19722	0.18		2	150,000	300,000	9
4	2005	17	8 Actual	0	8	2.07944	0.18		1	150,000	150,000	0
1	2006	18	11 Actual	0	11	2.39790	0.18		2	150,000	300,000	0
2	2006	19	5 Actual	0	5	1.60944	0.18		1	150,000	150,000	0
3	2006	20	8 Actual	0	8	2.07944	0.18		1	150,000	150,000	5
4	2006	21	15 Actual	0	15	2.70805	0.18		3	150,000	450,000	0
1	2007	22	10 Actual	0	10	2.30259	0.18		2	150,000	300,000	0
2	2007	23	7 Actual	0	7	1.94591	0.18		1	150,000	150,000	0
3	2007	24	10 Actual	0	10	2.30259	0.18		2	150,000	300,000	8
4	2007	25	12 Actual	0	12	2.48491	0.18		2	150,000	300,000	0
1	2008	26	9 Actual	0	9	2.19722	0.18		2	150,000	300,000	0
2	2008	27	7 Actual	0	7	1.94591	0.18		1	150,000	150,000	0
3	2008	28	7 Projected				0.18		1	150,000	150,000	6
4	2008	29	7 Projected				0.18		1	150,000	150,000	0
1	2009	30	6 Projected				0.18		1	150,000	150,000	0
2	2009	31	6 Projected				0.18		1	150,000	150,000	0
3	2009	32	6 Projected				0.18		1	150,000	150,000	4
4	2009	33	6 Projected				0.18		1	150,000	150,000	0
1	2010	34	5 Projected				0.18		1	150,000	150,000	0
2	2010	35	5 Projected				0.18		1	150,000	150,000	0
3	2010	36	5 Projected				0.18		1	150,000	150,000	4
4	2010	37	5 Projected				0.18		1	150,000	150,000	0
1	2011	38	4 Projected				0.18		1	150,000	150,000	0
2	2011	39	4 Projected				0.18		1	150,000	150,000	0
3	2011	40	4 Projected				0.18		1	150,000	150,000	4
4	2011	41	4 Projected				0.18		1	150,000	150,000	0
1	2012	42	4 Projected				0.18		1	150,000	150,000	0
2	2012	43	4 Projected				0.18		1	150,000	150,000	0
3	2012	44	3 Projected				0.18		1	150,000	150,000	4
4	2012	45	3 Projected				0.18		1	150,000	150,000	0
1	2013	46	3 Projected				0.18		1	150,000	150,000	0
2	2013	47	3 Projected				0.18		1	150,000	150,000	0
3	2013	48	3 Projected				0.18		1	150,000	150,000	4
4	2013	49	3 Projected				0.18		1	150,000	150,000	0
1	2014	50	3 Projected				0.18		1	150,000	150,000	0
2	2014	51	2 Projected				0.18		0	150,000	0	0
3	2014	52	2 Projected				0.18		0	150,000	0	2
4	2014	53	2 Projected				0.18		0	150,000	0	0
1	2015	54	2 Projected				0.18		0	150,000	0	0
2	2015	55	2 Projected				0.18		0	150,000	0	0
3	2015	56	2 Projected				0.18		0	150,000	0	0
4	2015	57	2 Projected				0.18		0	150,000	0	0
1	2016	58	2 Projected				0.18		0	150,000	0	0
2	2016	59	2 Projected				0.18		0	150,000	0	0
3	2016	60	2 Projected				0.18		0	150,000	0	0
4	2016	61	2 Projected				0.18		0	150,000	0	0
1	2017	62	2 Projected				0.18		0	150,000	0	0
2	2017	63	1 Projected				0.18		0	150,000	0	0
3	2017	64	1 Projected				0.18		0	150,000	0	0
4	2017	65	1 Projected				0.18		0	150,000	0	0
1	2018	66	1 Projected				0.18		0	150,000	0	0
2	2018	67	1 Projected				0.18		0	150,000	0	0
3	2018	68	1 Projected				0.18		0	150,000	0	0
4	2018	69	1 Projected				0.18		0	150,000	0	0
1	2019	70	1 Projected				0.18		0	150,000	0	0
2	2019	71	1 Projected				0.18		0	150,000	0	0

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR CHRONIC SILICOSIS CASES**

Exhibit 4

Parameters for fitted curve
m -0.0432 3.1019 b

Parameters Selected for
m -0.0450 3.2000 b

CASES BY QUARTER

Quarter Filed	(1) Year	(2) Number of Cases	(3) t	(4) Judgmental Adjustment	(5) y	(6) ln(y)	(7) = (3) + (5)	(8) -8.00	(9) Selected Approval Rate	(10) Approved Cases	(11) Case Amount	(12) Estimated Ultimate Compensation	(13) Approved Cases By Fiscal Year
3	2019	72		1 Projected				0.18	0	150,000	0	0	
4	2019	73		1 Projected				0.18	0	150,000	0	0	
1	2020	74		1 Projected				0.18	0	150,000	0	0	
2	2020	75		1 Projected				0.18	0	150,000	0	0	
3	2020	76		1 Projected				0.18	0	150,000	0	0	
4	2020	77		1 Projected				0.18	0	150,000	0	0	
1	2021	78		1 Projected				0.18	0	150,000	0	0	
2	2021	79		1 Projected				0.18	0	150,000	0	0	
3	2021	80		1 Projected				0.18	0	150,000	0	0	
4	2021	81		1 Projected				0.18	0	150,000	0	0	
1	2022	82		1 Projected				0.18	0	150,000	0	0	
2	2022	83		1 Projected				0.18	0	150,000	0	0	
3	2022	84		1 Projected				0.18	0	150,000	0	0	
4	2022	85		1 Projected				0.18	0	150,000	0	0	
1	2023	86		1 Projected				0.18	0	150,000	0	0	
2	2023	87		0 Projected				0.18	0	150,000	0	0	
3	2023	88		0 Projected				0.18	0	150,000	0	0	
4	2023	89		0 Projected				0.18	0	150,000	0	0	
1	2024	90		0 Projected				0.18	0	150,000	0	0	
2	2024	91		0 Projected				0.18	0	150,000	0	0	
3	2024	92		0 Projected				0.18	0	150,000	0	0	
4	2024	93		0 Projected				0.18	0	150,000	0	0	
1	2025	94		0 Projected				0.18	0	150,000	0	0	
2	2025	95		0 Projected				0.18	0	150,000	0	0	
3	2025	96		0 Projected				0.18	0	150,000	0	0	
4	2025	97		0 Projected				0.18	0	150,000	0	0	
1	2026	98		0 Projected				0.18	0	150,000	0	0	
2	2026	99		0 Projected				0.18	0	150,000	0	0	
3	2026	100		0 Projected				0.18	0	150,000	0	0	
4	2026	101		0 Projected				0.18	0	150,000	0	0	
1	2027	102		0 Projected				0.18	0	150,000	0	0	
2	2027	103		0 Projected				0.18	0	150,000	0	0	
3	2027	104		0 Projected				0.18	0	150,000	0	0	
4	2027	105		0 Projected				0.18	0	150,000	0	0	
1	2028	106		0 Projected				0.18	0	150,000	0	0	
2	2028	107		0 Projected				0.18	0	150,000	0	0	
3	2028	108		0 Projected				0.18	0	150,000	0	0	
4	2028	109		0 Projected				0.18	0	150,000	0	0	
1	2029	110		0 Projected				0.18	0	150,000	0	0	
2	2029	111		0 Projected				0.18	0	150,000	0	0	
3	2029	112		0 Projected				0.18	0	150,000	0	0	
4	2029	113		0 Projected				0.18	0	150,000	0	0	
1	2030	114		0 Projected				0.18	0	150,000	0	0	
2	2030	115		0 Projected				0.18	0	150,000	0	0	
3	2030	116		0 Projected				0.18	0	150,000	0	0	
		679								120	18,000,000	120	

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve
 Column (8) is from Exhibit 1 Page 2 Table 2
 Column (12) is the sum of column (9) for rows in the fiscal year

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR CANCER SEC CASES**

Exhibit 4

Parameters for fitted curve
m -0.0301 6.4476 b

Parameters Selected for
m -0.0300 6.7500 b

CASES BY QUARTER

Quarter Filed	Year	(3) Number of Cases	(4) Judgmental Adjustment	(5) y	(6) ln(y)	(7) Selected Approval Rate	(8) Approved Cases	(9) Case Amount	(10) Estimated Ultimate Compensation	(11) Approved Cases By Fiscal Year
3	2001	2,093 Actual	0	2093	7.64635	0.77	1612	150,000	241,800,000	1,612
4	2001	1 918 Actual	0	918	6.82220	0.77	707	150,000	106,050,000	0
1	2002	2 957 Actual	0	957	6.86380	0.77	737	150,000	110,550,000	0
2	2002	3 726 Actual	0	726	6.58755	0.77	559	150,000	83,850,000	0
3	2002	4 634 Actual	0	634	6.45205	0.77	488	150,000	73,200,000	2,491
4	2002	5 432 Actual	0	432	6.06843	0.77	333	150,000	49,950,000	0
1	2003	6 476 Actual	0	476	6.16542	0.77	367	150,000	55,050,000	0
2	2003	7 426 Actual	0	426	6.05444	0.77	328	150,000	49,200,000	0
3	2003	8 369 Actual	0	369	5.91080	0.77	284	150,000	42,600,000	1,312
4	2003	9 390 Actual	0	390	5.96615	0.77	300	150,000	45,000,000	0
1	2004	10 474 Actual	0	474	6.16121	0.77	365	150,000	54,750,000	0
2	2004	11 386 Actual	0	386	5.95584	0.77	297	150,000	44,550,000	0
3	2004	12 483 Actual	0	483	6.18002	0.77	372	150,000	55,800,000	1,334
4	2004	13 334 Actual	0	334	5.81114	0.77	257	150,000	38,550,000	0
1	2005	14 383 Actual	0	383	5.94803	0.77	295	150,000	44,250,000	0
2	2005	15 390 Actual	0	390	5.96615	0.77	300	150,000	45,000,000	0
3	2005	16 312 Actual	0	312	5.74300	0.77	240	150,000	36,000,000	1,092
4	2005	17 337 Actual	0	337	5.82008	0.77	259	150,000	38,850,000	0
1	2006	18 322 Actual	0	322	5.77455	0.77	248	150,000	37,200,000	0
2	2006	19 317 Actual	0	317	5.75890	0.77	244	150,000	36,600,000	0
3	2006	20 304 Actual	0	304	5.71703	0.77	234	150,000	35,100,000	985
4	2006	21 320 Actual	0	320	5.76832	0.77	246	150,000	36,900,000	0
1	2007	22 380 Actual	0	380	5.94017	0.77	293	150,000	43,950,000	0
2	2007	23 331 Actual	0	331	5.80212	0.77	255	150,000	38,250,000	0
3	2007	24 355 Actual	0	355	5.87212	0.77	273	150,000	40,950,000	1,067
4	2007	25 365 Actual	0	365	5.89990	0.77	281	150,000	42,150,000	0
1	2008	26 328 Actual	0	328	5.79301	0.77	253	150,000	37,950,000	0
2	2008	27 363 Actual	0	363	5.89440	0.77	280	150,000	42,000,000	0
3	2008	28 369 Projected				0.77	284	150,000	42,600,000	1,098
4	2008	29 358 Projected				0.77	276	150,000	41,400,000	0
1	2009	30 347 Projected				0.77	267	150,000	40,050,000	0
2	2009	31 337 Projected				0.77	259	150,000	38,850,000	0
3	2009	32 327 Projected				0.77	252	150,000	37,800,000	1,054
4	2009	33 317 Projected				0.77	244	150,000	36,600,000	0
1	2010	34 308 Projected				0.77	237	150,000	35,550,000	0
2	2010	35 299 Projected				0.77	230	150,000	34,500,000	0
3	2010	36 290 Projected				0.77	223	150,000	33,450,000	934
4	2010	37 281 Projected				0.77	216	150,000	32,400,000	0
1	2011	38 273 Projected				0.77	210	150,000	31,500,000	0
2	2011	39 265 Projected				0.77	204	150,000	30,600,000	0
3	2011	40 257 Projected				0.77	198	150,000	29,700,000	828
4	2011	41 250 Projected				0.77	193	150,000	28,950,000	0
1	2012	42 242 Projected				0.77	186	150,000	27,900,000	0
2	2012	43 235 Projected				0.77	181	150,000	27,150,000	0
3	2012	44 228 Projected				0.77	176	150,000	26,400,000	736
4	2012	45 221 Projected				0.77	170	150,000	25,500,000	0
1	2013	46 215 Projected				0.77	166	150,000	24,900,000	0
2	2013	47 209 Projected				0.77	161	150,000	24,150,000	0
3	2013	48 202 Projected				0.77	156	150,000	23,400,000	653
4	2013	49 196 Projected				0.77	151	150,000	22,650,000	0
1	2014	50 191 Projected				0.77	147	150,000	22,050,000	0
2	2014	51 185 Projected				0.77	142	150,000	21,300,000	0
3	2014	52 179 Projected				0.77	138	150,000	20,700,000	578
4	2014	53 174 Projected				0.77	134	150,000	20,100,000	0
1	2015	54 169 Projected				0.77	130	150,000	19,500,000	0
2	2015	55 164 Projected				0.77	126	150,000	18,900,000	0
3	2015	56 159 Projected				0.77	122	150,000	18,300,000	512
4	2015	57 154 Projected				0.77	119	150,000	17,850,000	0
1	2016	58 150 Projected				0.77	116	150,000	17,400,000	0
2	2016	59 145 Projected				0.77	112	150,000	16,800,000	0
3	2016	60 141 Projected				0.77	109	150,000	16,350,000	456
4	2016	61 137 Projected				0.77	105	150,000	15,750,000	0
1	2017	62 133 Projected				0.77	102	150,000	15,300,000	0
2	2017	63 129 Projected				0.77	99	150,000	14,850,000	0
3	2017	64 125 Projected				0.77	96	150,000	14,400,000	402
4	2017	65 122 Projected				0.77	94	150,000	14,100,000	0
1	2018	66 118 Projected				0.77	91	150,000	13,650,000	0
2	2018	67 114 Projected				0.77	88	150,000	13,200,000	0
3	2018	68 111 Projected				0.77	85	150,000	12,750,000	358
4	2018	69 108 Projected				0.77	83	150,000	12,450,000	0
1	2019	70 105 Projected				0.77	81	150,000	12,150,000	0
2	2019	71 101 Projected				0.77	78	150,000	11,700,000	0
3	2019	72 98 Projected				0.77	75	150,000	11,250,000	317
4	2019	73 96 Projected				0.77	74	150,000	11,100,000	0

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR CANCER SEC CASES**

Exhibit 4

Parameters for fitted curve
m -0.0301 6.4476 b

Parameters Selected for
m -0.0300 6.7500 b

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
						= (3) + (5)			= (4) x (8)		= (9) x (10)	
Quarter Filed	Year	Number of Cases		Judgmental Adjustment		y	ln(y)	Selected Approval Rate	Approved Cases	Case Amount	Estimated Ultimate Compensation	Approved Cases By Fiscal Year
1	2020	74	93	Projected				0.77	72	150,000	10,800,000	0
2	2020	75	90	Projected				0.77	69	150,000	10,350,000	0
3	2020	76	87	Projected				0.77	67	150,000	10,050,000	282
4	2020	77	85	Projected				0.77	65	150,000	9,750,000	0
1	2021	78	82	Projected				0.77	63	150,000	9,450,000	0
2	2021	79	80	Projected				0.77	62	150,000	9,300,000	0
3	2021	80	77	Projected				0.77	59	150,000	8,850,000	249
4	2021	81	75	Projected				0.77	58	150,000	8,700,000	0
1	2022	82	73	Projected				0.77	56	150,000	8,400,000	0
2	2022	83	71	Projected				0.77	55	150,000	8,250,000	0
3	2022	84	69	Projected				0.77	53	150,000	7,950,000	222
4	2022	85	67	Projected				0.77	52	150,000	7,800,000	0
1	2023	86	65	Projected				0.77	50	150,000	7,500,000	0
2	2023	87	63	Projected				0.77	49	150,000	7,350,000	0
3	2023	88	61	Projected				0.77	47	150,000	7,050,000	198
4	2023	89	59	Projected				0.77	45	150,000	6,750,000	0
1	2024	90	57	Projected				0.77	44	150,000	6,600,000	0
2	2024	91	56	Projected				0.77	43	150,000	6,450,000	0
3	2024	92	54	Projected				0.77	42	150,000	6,300,000	174
4	2024	93	52	Projected				0.77	40	150,000	6,000,000	0
1	2025	94	51	Projected				0.77	39	150,000	5,850,000	0
2	2025	95	49	Projected				0.77	38	150,000	5,700,000	0
3	2025	96	48	Projected				0.77	37	150,000	5,550,000	154
4	2025	97	47	Projected				0.77	36	150,000	5,400,000	0
1	2026	98	45	Projected				0.77	35	150,000	5,250,000	0
2	2026	99	44	Projected				0.77	34	150,000	5,100,000	0
3	2026	100	43	Projected				0.77	33	150,000	4,950,000	138
4	2026	101	41	Projected				0.77	32	150,000	4,800,000	0
1	2027	102	40	Projected				0.77	31	150,000	4,650,000	0
2	2027	103	39	Projected				0.77	30	150,000	4,500,000	0
3	2027	104	38	Projected				0.77	29	150,000	4,350,000	122
4	2027	105	37	Projected				0.77	28	150,000	4,200,000	0
1	2028	106	36	Projected				0.77	28	150,000	4,200,000	0
2	2028	107	34	Projected				0.77	26	150,000	3,900,000	0
3	2028	108	33	Projected				0.77	25	150,000	3,750,000	107
4	2028	109	32	Projected				0.77	25	150,000	3,750,000	0
1	2029	110	32	Projected				0.77	25	150,000	3,750,000	0
2	2029	111	31	Projected				0.77	24	150,000	3,600,000	0
3	2029	112	30	Projected				0.77	23	150,000	3,450,000	97
4	2029	113	29	Projected				0.77	22	150,000	3,300,000	0
1	2030	114	28	Projected				0.77	22	150,000	3,300,000	0
2	2030	115	27	Projected				0.77	21	150,000	3,150,000	0
3	2030	116	26	Projected				0.77	20	150,000	3,000,000	85
			25,515						19,647		2,947,050,000	19,647

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve
 Column (8) is from Exhibit 1 Page 2 Table 2
 Column (12) is the sum of column (9) for rows in the fiscal year

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR CANCER NON SEC CASES**

Exhibit 4

Parameters for fitted curve
m -0.0534 7.3256 b

Parameters Selected for
m -0.0550 7.2000 b

CASES BY QUARTER

(1)	(2)	(3)	(4)	(5)	(6)	(7)	-8.00	(9)	(10)	(11)	(12)
					= (3) + (5)			=(4) x (8)		=(9) x (10)	
Quarter Filed	Year	Number of Cases	Judgmental Adjustment	y	ln(y)	Selected Approval Rate	Approved Cases	Case Amount	Estimated Ultimate Compensation	Approved Cases By Fiscal Year	
3	2001	3,783 Actual	0	3783	8.23827	0.25	946	150,000	141,900,000	946	
4	2001	2,962 Actual	0	2962	7.99362	0.25	741	150,000	111,150,000	0	
1	2002	2,428 Actual	0	2428	7.79482	0.25	607	150,000	91,050,000	0	
2	2002	1,438 Actual	0	1438	7.27101	0.25	360	150,000	54,000,000	0	
3	2002	1,062 Actual	0	1062	6.96791	0.25	266	150,000	39,900,000	1,974	
4	2002	827 Actual	0	827	6.71780	0.25	207	150,000	31,050,000	0	
1	2003	878 Actual	0	878	6.77765	0.25	220	150,000	33,000,000	0	
2	2003	877 Actual	0	877	6.77651	0.25	219	150,000	32,850,000	0	
3	2003	802 Actual	0	802	6.68711	0.25	201	150,000	30,150,000	847	
4	2003	819 Actual	0	819	6.70808	0.25	205	150,000	30,750,000	0	
1	2004	939 Actual	0	939	6.84482	0.25	235	150,000	35,250,000	0	
2	2004	712 Actual	0	712	6.56808	0.25	178	150,000	26,700,000	0	
3	2004	788 Actual	0	788	6.66950	0.25	197	150,000	29,550,000	815	
4	2004	541 Actual	0	541	6.29342	0.25	135	150,000	20,250,000	0	
1	2005	733 Actual	0	733	6.59715	0.25	183	150,000	27,450,000	0	
2	2005	723 Actual	0	723	6.58341	0.25	181	150,000	27,150,000	0	
3	2005	616 Actual	0	616	6.42325	0.25	154	150,000	23,100,000	653	
4	2005	465 Actual	0	465	6.14204	0.25	116	150,000	17,400,000	0	
1	2006	490 Actual	0	490	6.19441	0.25	123	150,000	18,450,000	0	
2	2006	443 Actual	0	443	6.09357	0.25	111	150,000	16,650,000	0	
3	2006	462 Actual	0	462	6.13556	0.25	116	150,000	17,400,000	466	
4	2006	454 Actual	0	454	6.11810	0.25	114	150,000	17,100,000	0	
1	2007	746 Actual	0	746	6.61473	0.25	187	150,000	28,050,000	0	
2	2007	469 Actual	0	469	6.15060	0.25	117	150,000	17,550,000	0	
3	2007	514 Actual	0	514	6.24222	0.25	129	150,000	19,350,000	547	
4	2007	494 Actual	0	494	6.20254	0.25	124	150,000	18,600,000	0	
1	2008	386 Actual	0	386	5.95584	0.25	97	150,000	14,550,000	0	
2	2008	435 Actual	0	435	6.07535	0.25	109	150,000	16,350,000	0	
3	2008	287 Projected		287		0.25	72	150,000	10,800,000	402	
4	2008	272 Projected		272		0.25	68	150,000	10,200,000	0	
1	2009	257 Projected		257		0.25	64	150,000	9,600,000	0	
2	2009	243 Projected		243		0.25	61	150,000	9,150,000	0	
3	2009	230 Projected		230		0.25	58	150,000	8,700,000	251	
4	2009	218 Projected		218		0.25	55	150,000	8,250,000	0	
1	2010	206 Projected		206		0.25	52	150,000	7,800,000	0	
2	2010	195 Projected		195		0.25	49	150,000	7,350,000	0	
3	2010	185 Projected		185		0.25	46	150,000	6,900,000	202	
4	2010	175 Projected		175		0.25	44	150,000	6,600,000	0	
1	2011	166 Projected		166		0.25	42	150,000	6,300,000	0	
2	2011	157 Projected		157		0.25	39	150,000	5,850,000	0	
3	2011	148 Projected		148		0.25	37	150,000	5,550,000	162	
4	2011	140 Projected		140		0.25	35	150,000	5,250,000	0	
1	2012	133 Projected		133		0.25	33	150,000	4,950,000	0	
2	2012	126 Projected		126		0.25	32	150,000	4,800,000	0	
3	2012	119 Projected		119		0.25	30	150,000	4,500,000	130	
4	2012	113 Projected		113		0.25	28	150,000	4,200,000	0	
1	2013	107 Projected		107		0.25	27	150,000	4,050,000	0	
2	2013	101 Projected		101		0.25	25	150,000	3,750,000	0	
3	2013	96 Projected		96		0.25	24	150,000	3,600,000	104	
4	2013	90 Projected		90		0.25	23	150,000	3,450,000	0	
1	2014	86 Projected		86		0.25	22	150,000	3,300,000	0	
2	2014	81 Projected		81		0.25	20	150,000	3,000,000	0	
3	2014	77 Projected		77		0.25	19	150,000	2,850,000	84	
4	2014	73 Projected		73		0.25	18	150,000	2,700,000	0	
1	2015	69 Projected		69		0.25	17	150,000	2,550,000	0	
2	2015	65 Projected		65		0.25	16	150,000	2,400,000	0	
3	2015	62 Projected		62		0.25	16	150,000	2,400,000	67	
4	2015	58 Projected		58		0.25	15	150,000	2,250,000	0	
1	2016	55 Projected		55		0.25	14	150,000	2,100,000	0	
2	2016	52 Projected		52		0.25	13	150,000	1,950,000	0	
3	2016	49 Projected		49		0.25	12	150,000	1,800,000	54	
4	2016	47 Projected		47		0.25	12	150,000	1,800,000	0	
1	2017	44 Projected		44		0.25	11	150,000	1,650,000	0	
2	2017	42 Projected		42		0.25	11	150,000	1,650,000	0	
3	2017	40 Projected		40		0.25	10	150,000	1,500,000	44	
4	2017	38 Projected		38		0.25	10	150,000	1,500,000	0	
1	2018	36 Projected		36		0.25	9	150,000	1,350,000	0	
2	2018	34 Projected		34		0.25	9	150,000	1,350,000	0	
3	2018	32 Projected		32		0.25	8	150,000	1,200,000	36	
4	2018	30 Projected		30		0.25	8	150,000	1,200,000	0	
1	2019	29 Projected		29		0.25	7	150,000	1,050,000	0	
2	2019	27 Projected		27		0.25	7	150,000	1,050,000	0	
3	2019	26 Projected		26		0.25	7	150,000	1,050,000	29	
4	2019	24 Projected		24		0.25	6	150,000	900,000	0	

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR CANCER NON SEC CASES**

Exhibit 4

Parameters for fitted curve
m -0.0534 7.3256 b

Parameters Selected for
m -0.0550 7.2000 b

CASES BY QUARTER

(1)	(2)	(3)	(4)	(5)	(6)	(7)	-8.00	(9)	(10)	(11)	(12)
					= (3) + (5)			= (4) x (8)		= (9) x (10)	
Quarter Filed	Year	Number of Cases		Judgmental Adjustment	y	ln(y)	Selected Approval Rate	Approved Cases	Case Amount	Estimated Ultimate Compensation	Approved Cases By Fiscal Year
1	2020	74	23 Projected				0.25	6	150,000	900,000	0
2	2020	75	22 Projected				0.25	6	150,000	900,000	0
3	2020	76	20 Projected				0.25	5	150,000	750,000	23
4	2020	77	19 Projected				0.25	5	150,000	750,000	0
1	2021	78	18 Projected				0.25	5	150,000	750,000	0
2	2021	79	17 Projected				0.25	4	150,000	600,000	0
3	2021	80	16 Projected				0.25	4	150,000	600,000	18
4	2021	81	16 Projected				0.25	4	150,000	600,000	0
1	2022	82	15 Projected				0.25	4	150,000	600,000	0
2	2022	83	14 Projected				0.25	4	150,000	600,000	0
3	2022	84	13 Projected				0.25	3	150,000	450,000	15
4	2022	85	12 Projected				0.25	3	150,000	450,000	0
1	2023	86	12 Projected				0.25	3	150,000	450,000	0
2	2023	87	11 Projected				0.25	3	150,000	450,000	0
3	2023	88	11 Projected				0.25	3	150,000	450,000	12
4	2023	89	10 Projected				0.25	3	150,000	450,000	0
1	2024	90	9 Projected				0.25	2	150,000	300,000	0
2	2024	91	9 Projected				0.25	2	150,000	300,000	0
3	2024	92	8 Projected				0.25	2	150,000	300,000	9
4	2024	93	8 Projected				0.25	2	150,000	300,000	0
1	2025	94	8 Projected				0.25	2	150,000	300,000	0
2	2025	95	7 Projected				0.25	2	150,000	300,000	0
3	2025	96	7 Projected				0.25	2	150,000	300,000	8
4	2025	97	6 Projected				0.25	2	150,000	300,000	0
1	2026	98	6 Projected				0.25	2	150,000	300,000	0
2	2026	99	6 Projected				0.25	2	150,000	300,000	0
3	2026	100	5 Projected				0.25	1	150,000	150,000	7
4	2026	101	5 Projected				0.25	1	150,000	150,000	0
1	2027	102	5 Projected				0.25	1	150,000	150,000	0
2	2027	103	5 Projected				0.25	1	150,000	150,000	0
3	2027	104	4 Projected				0.25	1	150,000	150,000	4
4	2027	105	4 Projected				0.25	1	150,000	150,000	0
1	2028	106	4 Projected				0.25	1	150,000	150,000	0
2	2028	107	4 Projected				0.25	1	150,000	150,000	0
3	2028	108	4 Projected				0.25	1	150,000	150,000	4
4	2028	109	3 Projected				0.25	1	150,000	150,000	0
1	2029	110	3 Projected				0.25	1	150,000	150,000	0
2	2029	111	3 Projected				0.25	1	150,000	150,000	0
3	2029	112	3 Projected				0.25	1	150,000	150,000	4
4	2029	113	3 Projected				0.25	1	150,000	150,000	0
1	2030	114	3 Projected				0.25	1	150,000	150,000	0
2	2030	115	2 Projected				0.25	1	150,000	150,000	0
3	2030	116	2 Projected				0.25	1	150,000	150,000	4
		31,611						7,921		1,188,150,000	7,921

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve
 Column (8) is from Exhibit 1 Page 2 Table 2
 Column (12) is the sum of column (9) for rows in the fiscal year

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR BERYLLIUM SENSITIVITY CASES**

Exhibit 4

Parameters for fitted curve
m -0.0434 4.7423 b

Parameters Selected for
m -0.0434 4.9000 b

CASES BY QUARTER

(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) = (4) x (8)	(10)	(11) = (9) x (10)	(12)
Quarter Filed	Year	Number of Cases	Judgmental Adjustment	y	ln(y)	Selected Approval Rate	Approved Cases	Case Amount	Estimated Ultimate Compensation	Approved Cases By Fiscal Year	
3	2001	198 Actual	0	198	5.28827	0.56	111	0	0	111	
4	2001	114 Actual	0	114	4.73620	0.56	64	0	0	0	
1	2002	146 Actual	0	146	4.98361	0.56	82	0	0	0	
2	2002	194 Actual	0	194	5.26786	0.56	109	0	0	0	
3	2002	153 Actual	0	153	5.03044	0.56	86	0	0	341	
4	2002	94 Actual	0	94	4.54329	0.56	53	0	0	0	
1	2003	86 Actual	0	86	4.45435	0.56	48	0	0	0	
2	2003	92 Actual	0	92	4.52179	0.56	52	0	0	0	
3	2003	71 Actual	0	71	4.26268	0.56	40	0	0	193	
4	2003	52 Actual	0	52	3.95124	0.56	29	0	0	0	
1	2004	49 Actual	0	49	3.89182	0.56	27	0	0	0	
2	2004	45 Actual	0	45	3.80666	0.56	25	0	0	0	
3	2004	119 Actual	0	119	4.77912	0.56	67	0	0	148	
4	2004	33 Actual	0	33	3.49651	0.56	18	0	0	0	
1	2005	57 Actual	0	57	4.04305	0.56	32	0	0	0	
2	2005	55 Actual	0	55	4.00733	0.56	31	0	0	0	
3	2005	47 Actual	0	47	3.85015	0.56	26	0	0	107	
4	2005	28 Actual	0	28	3.33220	0.56	16	0	0	0	
1	2006	26 Actual	0	26	3.25810	0.56	15	0	0	0	
2	2006	47 Actual	0	47	3.85015	0.56	26	0	0	0	
3	2006	44 Actual	0	44	3.78419	0.56	25	0	0	82	
4	2006	74 Actual	0	74	4.30407	0.56	41	0	0	0	
1	2007	71 Actual	0	71	4.26268	0.56	40	0	0	0	
2	2007	42 Actual	0	42	3.73767	0.56	24	0	0	0	
3	2007	64 Actual	0	64	4.15888	0.56	36	0	0	141	
4	2007	42 Actual	0	42	3.73767	0.56	24	0	0	0	
1	2008	46 Actual	0	46	3.82864	0.56	26	0	0	0	
2	2008	43 Actual	0	43	3.76120	0.56	24	0	0	0	
3	2008	40 Projected				0.56	22	0	0	96	
4	2008	38 Projected				0.56	21	0	0	0	
1	2009	37 Projected				0.56	21	0	0	0	
2	2009	35 Projected				0.56	20	0	0	0	
3	2009	33 Projected				0.56	18	0	0	80	
4	2009	32 Projected				0.56	18	0	0	0	
1	2010	31 Projected				0.56	17	0	0	0	
2	2010	29 Projected				0.56	16	0	0	0	
3	2010	28 Projected				0.56	16	0	0	67	
4	2010	27 Projected				0.56	15	0	0	0	
1	2011	38 Projected				0.56	15	0	0	0	
2	2011	25 Projected				0.56	14	0	0	0	
3	2011	24 Projected				0.56	13	0	0	57	
4	2011	23 Projected				0.56	13	0	0	0	
1	2012	22 Projected				0.56	12	0	0	0	
2	2012	21 Projected				0.56	12	0	0	0	
3	2012	20 Projected				0.56	11	0	0	48	
4	2012	19 Projected				0.56	11	0	0	0	
1	2013	18 Projected				0.56	10	0	0	0	
2	2013	17 Projected				0.56	10	0	0	0	
3	2013	17 Projected				0.56	10	0	0	41	
4	2013	16 Projected				0.56	9	0	0	0	
1	2014	15 Projected				0.56	8	0	0	0	
2	2014	15 Projected				0.56	8	0	0	0	
3	2014	14 Projected				0.56	8	0	0	33	
4	2014	13 Projected				0.56	7	0	0	0	
1	2015	13 Projected				0.56	7	0	0	0	
2	2015	12 Projected				0.56	7	0	0	0	
3	2015	12 Projected				0.56	7	0	0	28	
4	2015	11 Projected				0.56	6	0	0	0	
1	2016	11 Projected				0.56	6	0	0	0	
2	2016	10 Projected				0.56	6	0	0	0	
3	2016	10 Projected				0.56	6	0	0	24	
4	2016	10 Projected				0.56	6	0	0	0	
1	2017	9 Projected				0.56	5	0	0	0	
2	2017	9 Projected				0.56	5	0	0	0	
3	2017	8 Projected				0.56	4	0	0	20	
4	2017	8 Projected				0.56	4	0	0	0	
1	2018	8 Projected				0.56	4	0	0	0	
2	2018	7 Projected				0.56	4	0	0	0	
3	2018	7 Projected				0.56	4	0	0	16	
4	2018	7 Projected				0.56	4	0	0	0	
1	2019	6 Projected				0.56	3	0	0	0	
2	2019	6 Projected				0.56	3	0	0	0	

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR BERYLLIUM SENSITIVITY CASES**

Exhibit 4

Parameters for fitted curve
m -0.0434 4.7423 b

Parameters Selected for
m -0.0434 4.9000 b

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) = (4) x (8)	(10)	(11) = (9) x (10)	(12)
Quarter Filed	Year	Number of Cases	Judgmental Adjustment	y	ln(y)	Selected Approval Rate	Approved Cases	Case Amount	Estimated Ultimate Compensation	Approved Cases By Fiscal Year		
3	2019	72	6 Projected			0.56	3	0	0	13		
4	2019	73	6 Projected			0.56	3	0	0	0		
1	2020	74	5 Projected			0.56	3	0	0	0		
2	2020	75	5 Projected			0.56	3	0	0	0		
3	2020	76	5 Projected			0.56	3	0	0	12		
4	2020	77	5 Projected			0.56	3	0	0	0		
1	2021	78	5 Projected			0.56	3	0	0	0		
2	2021	79	4 Projected			0.56	2	0	0	0		
3	2021	80	4 Projected			0.56	2	0	0	10		
4	2021	81	4 Projected			0.56	2	0	0	0		
1	2022	82	4 Projected			0.56	2	0	0	0		
2	2022	83	4 Projected			0.56	2	0	0	0		
3	2022	84	4 Projected			0.56	2	0	0	8		
4	2022	85	3 Projected			0.56	2	0	0	0		
1	2023	86	3 Projected			0.56	2	0	0	0		
2	2023	87	3 Projected			0.56	2	0	0	0		
3	2023	88	3 Projected			0.56	2	0	0	8		
4	2023	89	3 Projected			0.56	2	0	0	0		
1	2024	90	3 Projected			0.56	2	0	0	0		
2	2024	91	3 Projected			0.56	2	0	0	0		
3	2024	92	2 Projected			0.56	1	0	0	7		
4	2024	93	2 Projected			0.56	1	0	0	0		
1	2025	94	2 Projected			0.56	1	0	0	0		
2	2025	95	2 Projected			0.56	1	0	0	0		
3	2025	96	2 Projected			0.56	1	0	0	4		
4	2025	97	2 Projected			0.56	1	0	0	0		
1	2026	98	2 Projected			0.56	1	0	0	0		
2	2026	99	2 Projected			0.56	1	0	0	0		
3	2026	100	2 Projected			0.56	1	0	0	4		
4	2026	101	2 Projected			0.56	1	0	0	0		
1	2027	102	2 Projected			0.56	1	0	0	0		
2	2027	103	2 Projected			0.56	1	0	0	0		
3	2027	104	1 Projected			0.56	1	0	0	4		
4	2027	105	1 Projected			0.56	1	0	0	0		
1	2028	106	1 Projected			0.56	1	0	0	0		
2	2028	107	1 Projected			0.56	1	0	0	0		
3	2028	108	1 Projected			0.56	1	0	0	4		
4	2028	109	1 Projected			0.56	1	0	0	0		
1	2029	110	1 Projected			0.56	1	0	0	0		
2	2029	111	1 Projected			0.56	1	0	0	0		
3	2029	112	1 Projected			0.56	1	0	0	4		
4	2029	113	1 Projected			0.56	1	0	0	0		
1	2030	114	1 Projected			0.56	1	0	0	0		
2	2030	115	1 Projected			0.56	1	0	0	0		
3	2030	116	1 Projected			0.56	1	0	0	4		
		3,050					1,715		0	1,715		

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve
 Column (8) is from Exhibit 1 Page 2 Table 2
 Column (12) is the sum of column (9) for rows in the fiscal year

PROJECTED APPROVED CASES BY QUARTER FILED
FOR PART E CASES

Exhibit 4

Parameters for fitted curve
m -0.0163 7.7269 b

Parameters Selected for
m -0.0250 7.9000 b

CASES BY QUARTER

Quarter Filed	Year	(1) Number of Cases	(2)	(3) Judgmental Adjustment	(4) y	(5) ln(y)	(6) = (3) + (5)	(7)	(8) Selected Approval Rate	(9) Approved Cases	(10) Case Amount	(11) = (9) x (10) Estimated Ultimate Compensation	(12) Approved Cases By Fiscal Year
3	2001	2,149	Actual	0	2149	7.67276		0.40	860	143,000	122,980,000	860	
4	2001	2,052	Actual	0	2052	7.62657		0.40	821	143,000	117,403,000	0	
1	2002	2,810	Actual	0	2810	7.94094		0.40	1124	143,000	160,732,000	0	
2	2002	2,403	Actual	0	2403	7.78447		0.40	961	143,000	137,423,000	0	
3	2002	2,055	Actual	0	2055	7.62903		0.40	822	143,000	117,546,000	3728	
4	2002	1,715	Actual	0	1715	7.44717		0.40	686	143,000	98,098,000	0	
1	2003	1,600	Actual	0	1600	7.37776		0.40	640	143,000	91,520,000	0	
2	2003	2,159	Actual	0	2159	7.67740		0.40	864	143,000	123,552,000	0	
3	2003	2,046	Actual	0	2046	7.62364		0.40	818	143,000	116,974,000	3008	
4	2003	1,823	Actual	0	1823	7.50824		0.40	729	143,000	104,247,000	0	
1	2004	1,846	Actual	0	1846	7.52078		0.40	738	143,000	105,534,000	0	
2	2004	1,143	Actual	0	1143	7.04141		0.40	457	143,000	65,351,000	0	
3	2004	1,336	Actual	0	1336	7.19744		0.40	534	143,000	76,362,000	2458	
4	2004	1,767	Actual	0	1767	7.47704		0.40	707	143,000	101,101,000	0	
1	2005	1,429	Actual	0	1429	7.26473		0.40	523	143,000	75,219,000	0	
2	2005	1,432	Actual	0	1432	7.26683		0.40	524	143,000	75,258,000	0	
3	2005	1,342	Actual	0	1342	7.20192		0.40	537	143,000	76,791,000	0	
4	2005	1,210	Actual	0	1210	7.09838		0.40	484	143,000	69,212,000	0	
2	2006	1,360	Actual	0	1360	7.21524		0.40	544	143,000	77,792,000	0	
3	2006	1,339	Projected	0	1339	7.20000		0.40	536	143,000	76,648,000	2101	
4	2006	1,306	Projected	0	1306	7.18000		0.40	522	143,000	74,646,000	0	
1	2009	1,274	Projected	0	1274	7.15000		0.40	510	143,000	72,930,000	0	
2	2009	1,243	Projected	0	1243	7.12000		0.40	497	143,000	71,071,000	0	
3	2009	1,212	Projected	0	1212	7.09000		0.40	485	143,000	69,355,000	2014	
4	2009	1,182	Projected	0	1182	7.06000		0.40	473	143,000	67,639,000	0	
1	2010	1,153	Projected	0	1153	7.03000		0.40	461	143,000	65,923,000	0	
2	2010	1,124	Projected	0	1124	7.00000		0.40	450	143,000	64,350,000	0	
3	2010	1,097	Projected	0	1097	6.97000		0.40	439	143,000	62,777,000	1823	
4	2010	1,070	Projected	0	1070	6.94000		0.40	428	143,000	61,204,000	0	
1	2011	1,043	Projected	0	1043	6.91000		0.40	417	143,000	59,631,000	0	
2	2011	1,017	Projected	0	1017	6.88000		0.40	407	143,000	58,201,000	0	
3	2011	992	Projected	0	992	6.85000		0.40	397	143,000	56,771,000	1649	
4	2011	968	Projected	0	968	6.82000		0.40	387	143,000	55,341,000	0	
1	2012	944	Projected	0	944	6.79000		0.40	378	143,000	54,054,000	0	
2	2012	921	Projected	0	921	6.76000		0.40	368	143,000	52,624,000	0	
3	2012	898	Projected	0	898	6.73000		0.40	359	143,000	51,337,000	1492	
4	2012	876	Projected	0	876	6.70000		0.40	350	143,000	50,050,000	0	
1	2013	854	Projected	0	854	6.67000		0.40	342	143,000	48,906,000	0	
2	2013	833	Projected	0	833	6.64000		0.40	333	143,000	47,619,000	0	
3	2013	812	Projected	0	812	6.61000		0.40	325	143,000	46,475,000	1350	
4	2013	792	Projected	0	792	6.58000		0.40	317	143,000	45,331,000	0	
1	2014	773	Projected	0	773	6.55000		0.40	309	143,000	44,187,000	0	
2	2014	754	Projected	0	754	6.52000		0.40	302	143,000	43,186,000	0	
3	2014	735	Projected	0	735	6.49000		0.40	294	143,000	42,042,000	1222	
4	2014	717	Projected	0	717	6.46000		0.40	287	143,000	41,041,000	0	
1	2015	699	Projected	0	699	6.43000		0.40	280	143,000	40,040,000	0	
2	2015	682	Projected	0	682	6.40000		0.40	273	143,000	39,039,000	0	
3	2015	665	Projected	0	665	6.37000		0.40	266	143,000	38,038,000	1106	
4	2015	649	Projected	0	649	6.34000		0.40	260	143,000	37,180,000	0	
1	2016	633	Projected	0	633	6.31000		0.40	253	143,000	36,179,000	0	
2	2016	617	Projected	0	617	6.28000		0.40	247	143,000	35,321,000	0	
3	2016	602	Projected	0	602	6.25000		0.40	241	143,000	34,463,000	1001	
4	2016	587	Projected	0	587	6.22000		0.40	235	143,000	33,605,000	0	
1	2017	572	Projected	0	572	6.19000		0.40	229	143,000	32,747,000	0	
2	2017	558	Projected	0	558	6.16000		0.40	223	143,000	31,889,000	0	
3	2017	545	Projected	0	545	6.13000		0.40	218	143,000	31,174,000	905	
4	2017	531	Projected	0	531	6.10000		0.40	212	143,000	30,316,000	0	
1	2018	518	Projected	0	518	6.07000		0.40	207	143,000	29,601,000	0	
2	2018	505	Projected	0	505	6.04000		0.40	202	143,000	28,886,000	0	
3	2018	493	Projected	0	493	6.01000		0.40	197	143,000	28,171,000	818	
4	2018	481	Projected	0	481	5.98000		0.40	192	143,000	27,456,000	0	
1	2019	469	Projected	0	469	5.95000		0.40	188	143,000	26,884,000	0	
2	2019	457	Projected	0	457	5.92000		0.40	183	143,000	26,169,000	0	
3	2019	446	Projected	0	446	5.89000		0.40	178	143,000	25,454,000	741	
4	2019	435	Projected	0	435	5.86000		0.40	174	143,000	24,882,000	0	
1	2020	424	Projected	0	424	5.83000		0.40	170	143,000	24,310,000	0	
2	2020	414	Projected	0	414	5.80000		0.40	166	143,000	23,738,000	0	
3	2020	403	Projected	0	403	5.77000		0.40	161	143,000	23,023,000	671	
4	2020	393	Projected	0	393	5.74000		0.40	157	143,000	22,451,000	0	
1	2021	384	Projected	0	384	5.71000		0.40	154	143,000	22,022,000	0	
2	2021	374	Projected	0	374	5.68000		0.40	150	143,000	21,450,000	0	
3	2021	365	Projected	0	365	5.65000		0.40	146	143,000	20,878,000	607	
4	2021	356	Projected	0	356	5.62000		0.40	142	143,000	20,306,000	0	
1	2022	347	Projected	0	347	5.59000		0.40	139	143,000	19,877,000	0	
2	2022	339	Projected	0	339	5.56000		0.40	136	143,000	19,448,000	0	
3	2022	330	Projected	0	330	5.53000		0.40	132	143,000	18,876,000	549	
4	2022	322	Projected	0	322	5.50000		0.40	129	143,000	18,447,000	0	
1	2023	314	Projected	0	314	5.47000		0.40	126	143,000	18,018,000	0	
2	2023	306	Projected	0	306	5.44000		0.40	122	143,000	17,446,000	0	
3	2023	299	Projected	0	299	5.41000		0.40	120	143,000	17,163,000	497	
4	2023	291	Projected	0	291	5.38000		0.40	116	143,000	16,588,000	0	
1	2024	284	Projected	0	284	5.35000		0.40	114	143,000	16,302,000	0	
2	2024	277	Projected	0	277	5.32000		0.40	111	143,000	15,873,000	0	
3	2024	270	Projected	0	270	5.29000		0.40	108	143,000	15,444,000	449	
4	2024	264	Projected	0	264	5.26000		0.40	106	143,000	15,158,000	0	
1	2025	257	Projected	0	257	5.23000		0.40	103	143,000	14,729,000	0	
2	2025	251	Projected	0	251	5.20000		0.40	100	143,000	14,300,000	0	
3	2025	245	Projected	0	245	5.17000		0.40	98	143,000	14,014,000	407	
4	2025	239	Projected	0	239	5.14000		0.40	96	143,000	13,728,000	0	
1	2026	233	Projected	0	233	5.11000		0.40	93	143,000	13,299,000	0	
2	2026	227	Projected	0	227	5.08000		0.40	91	143,000	13,013,000	0	
3	2026	221	Projected	0	221	5.05000		0.40	88	143,000	12,584,000	368	
4	2026	216	Projected	0	216	5.02000		0.40	86	143,000	12,298,000	0	
1	2027	211	Projected	0	211	5.00000		0.40	84	143,000	12,012,000	0	

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR PART E CASES**

Exhibit 4

Parameters for fitted curve
m -0.0163 7.7269 b

Parameters Selected for
m -0.0250 7.9000 b

CASES BY QUARTER

Quarter Filed	Year	(1) t	(2) Number of Cases	(3) Judgmental Adjustment	(4) y	(5) ln(y)	(6) = (3) + (5)	(7) Selected Approval Rate	(8) Approved Cases	(9) = (4) x (8)	(10) Case Amount	(11) Estimated Ultimate Compensation	(12) Approved Cases By Fiscal Year
2	2027	103	205 Projected					0.40	82	143,000	11,726,000	0	
3	2027	104	200 Projected					0.40	80	143,000	11,440,000	332	
4	2027	105	195 Projected					0.40	78	143,000	11,154,000	0	
1	2028	106	191 Projected					0.40	76	143,000	10,868,000	0	
2	2028	107	186 Projected					0.40	74	143,000	10,582,000	0	
3	2028	108	181 Projected					0.40	72	143,000	10,296,000	300	
4	2028	109	177 Projected					0.40	71	143,000	10,153,000	0	
1	2029	110	172 Projected					0.40	69	143,000	9,867,000	0	
2	2029	111	168 Projected					0.40	67	143,000	9,581,000	0	
3	2029	112	164 Projected					0.40	66	143,000	9,438,000	273	
4	2029	113	160 Projected					0.40	64	143,000	9,152,000	0	
1	2030	114	156 Projected					0.40	62	143,000	8,866,000	0	
2	2030	115	152 Projected					0.40	61	143,000	8,723,000	0	
3	2030	116	148 Projected					0.40	59	143,000	8,437,000	246	
4	2030	116	148 Projected					0.40	59	143,000	8,437,000	0	
1	2031	117	145 Projected					0.40	58	143,000	8,294,000	0	
2	2031	118	141 Projected					0.40	56	143,000	8,008,000	0	
3	2031	119	138 Projected					0.40	55	143,000	7,865,000	228	
4	2031	120	134 Projected					0.40	54	143,000	7,722,000	0	
1	2032	121	131 Projected					0.40	52	143,000	7,436,000	0	
2	2032	122	128 Projected					0.40	51	143,000	7,293,000	0	
3	2032	123	125 Projected					0.40	50	143,000	7,150,000	207	
4	2032	124	122 Projected					0.40	49	143,000	7,007,000	0	
1	2033	125	119 Projected					0.40	48	143,000	6,864,000	0	
2	2033	126	116 Projected					0.40	46	143,000	6,578,000	0	
3	2033	127	113 Projected					0.40	45	143,000	6,435,000	188	
4	2033	128	110 Projected					0.40	44	143,000	6,292,000	0	
1	2034	129	107 Projected					0.40	43	143,000	6,149,000	0	
2	2034	130	105 Projected					0.40	42	143,000	6,006,000	0	
3	2034	131	102 Projected					0.40	41	143,000	5,863,000	170	
4	2034	132	99 Projected					0.40	40	143,000	5,720,000	0	
1	2035	133	97 Projected					0.40	39	143,000	5,577,000	0	
2	2035	134	95 Projected					0.40	38	143,000	5,434,000	0	
3	2035	135	92 Projected					0.40	37	143,000	5,291,000	154	
4	2035	136	90 Projected					0.40	36	143,000	5,148,000	0	
1	2036	137	88 Projected					0.40	35	143,000	5,005,000	0	
2	2036	138	86 Projected					0.40	34	143,000	4,862,000	0	
3	2036	139	84 Projected					0.40	34	143,000	4,862,000	139	
4	2036	140	81 Projected					0.40	32	143,000	4,576,000	0	
1	2037	141	79 Projected					0.40	32	143,000	4,576,000	0	
2	2037	142	77 Projected					0.40	31	143,000	4,433,000	0	
3	2037	143	76 Projected					0.40	30	143,000	4,290,000	125	
4	2037	144	74 Projected					0.40	30	143,000	4,290,000	0	
1	2038	145	72 Projected					0.40	29	143,000	4,147,000	0	
2	2038	146	70 Projected					0.40	28	143,000	4,004,000	0	
3	2038	147	68 Projected					0.40	27	143,000	3,861,000	114	
4	2038	148	67 Projected					0.40	27	143,000	3,861,000	0	
1	2039	149	65 Projected					0.40	26	143,000	3,718,000	0	
2	2039	150	63 Projected					0.40	25	143,000	3,575,000	0	
3	2039	151	62 Projected					0.40	25	143,000	3,575,000	103	
4	2039	152	60 Projected					0.40	24	143,000	3,432,000	0	
1	2040	153	59 Projected					0.40	24	143,000	3,432,000	0	
2	2040	154	57 Projected					0.40	23	143,000	3,289,000	0	
3	2040	155	56 Projected					0.40	22	143,000	3,146,000	93	
4	2040	156	55 Projected					0.40	22	143,000	3,146,000	0	
1	2041	157	53 Projected					0.40	21	143,000	3,003,000	0	
2	2041	158	52 Projected					0.40	21	143,000	3,003,000	0	
3	2041	159	51 Projected					0.40	20	143,000	2,860,000	84	
4	2041	160	49 Projected					0.40	20	143,000	2,860,000	0	
1	2042	161	48 Projected					0.40	19	143,000	2,717,000	0	
2	2042	162	47 Projected					0.40	19	143,000	2,717,000	0	
3	2042	163	46 Projected					0.40	18	143,000	2,574,000	76	
4	2042	164	45 Projected					0.40	18	143,000	2,574,000	0	
1	2043	165	44 Projected					0.40	18	143,000	2,574,000	0	
2	2043	166	43 Projected					0.40	17	143,000	2,431,000	0	
3	2043	167	41 Projected					0.40	16	143,000	2,288,000	69	
4	2043	168	40 Projected					0.40	16	143,000	2,288,000	0	
1	2044	169	39 Projected					0.40	16	143,000	2,288,000	0	
2	2044	170	38 Projected					0.40	15	143,000	2,145,000	0	
3	2044	171	38 Projected					0.40	15	143,000	2,145,000	62	
4	2044	172	37 Projected					0.40	15	143,000	2,145,000	0	
1	2045	173	36 Projected					0.40	14	143,000	2,002,000	0	
2	2045	174	35 Projected					0.40	14	143,000	2,002,000	0	
3	2045	175	34 Projected					0.40	14	143,000	2,002,000	57	
		105,894							42,359		6,057,337,000	42,359	

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve
 Column (8) is from Exhibit 1 Page 2 Table 2
 Column (12) is the sum of column (9) for rows in the fiscal year

Table 1

ESTIMATED CASES BY FISCAL YEAR FILED THAT ARE ULTIMATELY APPROVED UNDER EEOIC

(1) Filing Date	(2) RECA	(3) BD	(4) CS	(5) CN - SEC	(6) CN-NON SEC	(7) BS	(8) PART E	(9) TOTAL
7/01-9/01	1,457	435	22	1,612	946	111	860	5,443
10/01-9/02	1,018	564	29	2,491	1,974	341	3,728	10,145
10/02-9/03	487	300	9	1,312	847	193	3,008	6,156
10/03-9/04	580	389	10	1,334	815	148	2,458	5,734
10/04-9/05	818	207	9	1,092	653	107	4,257	7,143
10/05-9/06	763	81	5	985	466	82	2,633	5,015
10/06-9/07	728	96	8	1,067	547	141	2,625	5,212
10/07-9/08	581	57	6	1,098	402	96	2,101	4,341
10/08-9/09	527	42	4	1,054	251	80	2,014	3,972
10/09-9/10	459	29	4	934	202	67	1,823	3,518
10/10-9/11	399	22	4	828	162	57	1,649	3,121
10/11-9/12	347	16	4	736	130	48	1,492	2,773
10/12-9/13	302	12	4	653	104	41	1,350	2,466
10/13-9/14	263	8	2	578	84	33	1,222	2,190
10/14-9/15	228	8	0	512	67	28	1,106	1,949
10/15-9/16	197	4	0	456	54	24	1,001	1,736
10/16-9/17	173	4	0	402	44	20	905	1,548
10/17-9/18	149	4	0	358	36	16	818	1,381
10/18-9/19	129	4	0	317	29	13	741	1,233
10/19-9/20	113	4	0	282	23	12	671	1,105
10/20-9/21	99	0	0	249	18	10	607	983
10/21-9/22	86	0	0	222	15	8	549	880
10/22-9/23	75	0	0	198	12	8	497	790
10/23-9/24	64	0	0	174	9	7	449	703
10/24-9/25	56	0	0	154	8	4	407	629
10/25-9/26	48	0	0	138	7	4	368	565
10/26-9/27	41	0	0	122	4	4	332	503
10/27-9/28	39	0	0	107	4	4	300	454
10/28-9/29	34	0	0	97	4	4	273	412
10/29-9/30	29	0	0	85	4	4	246	368
10/30-9/31							228	228
10/31-9/32							207	207
10/32-9/33							188	188
10/33-9/34							170	170
10/34-9/35							154	154
10/35-9/36							139	139
10/36-9/37							125	125
10/37-9/38							114	114
10/38-9/39							103	103
10/39-9/40							93	93
10/40-9/41							84	84
10/41-9/42							76	76
10/42-9/43							69	69
10/43-9/44							62	62
10/44-9/45							57	57
Total	10,289	2,286	120	19,647	7,921	1,715	42,359	84,337

Columns (2) - (8) Data are from Exhibit 4 Column (12) for the respective disease

Table 2

ESTIMATED NUMBER OF PAID CASES BY FISCAL YEAR							
Fiscal Yr Pd	RECA	BD	CS	CN - SEC	CN-NON SEC	PART E	TOTAL
7/01-9/01	56	1	1	34	0	0	92
10/01-9/02	1,781	406	26	1,298	3	0	3,514
10/02-9/03	762	396	16	1,235	138	0	2,547
10/03-9/04	572	299	5	658	503	0	2,037
10/04-9/05	579	241	12	771	983	1,554	4,140
10/05-9/06	470	197	7	1,355	1,356	2,176	5,561
10/06-9/07	1,021	157	10	1,458	1,158	3,218	7,022
10/07-9/08	675	131	8	1,999	735	4,307	7,855
10/08-9/09	568	126	7	1,857	713	3,537	6,808
10/09-9/10	514	87	6	1,380	567	3,112	5,666
10/10-9/11	446	72	4	934	416	2,505	4,377
10/11-9/12	386	59	4	828	367	1,981	3,625
10/12-9/13	334	50	4	736	326	1,894	3,344
10/13-9/14	302	16	4	653	130	1,703	2,808
10/14-9/15	263	12	4	578	104	1,529	2,490
10/15-9/16	228	8	2	512	84	1,372	2,206
10/16-9/17	197	8	0	456	67	1,230	1,958
10/17-9/18	173	4	0	402	54	1,102	1,735
10/18-9/19	149	4	0	358	44	1,106	1,661
10/19-9/20	129	4	0	317	36	1,001	1,487
10/20-9/21	113	4	0	282	29	905	1,333
10/21-9/22	99	4	0	249	23	818	1,193
10/22-9/23	86	0	0	222	18	741	1,067
10/23-9/24	75	0	0	198	15	671	959
10/24-9/25	64	0	0	174	12	607	857
10/25-9/26	56	0	0	154	9	549	768
10/26-9/27	48	0	0	138	8	497	691
10/27-9/28	41	0	0	122	7	449	619
10/28-9/29	39	0	0	107	4	407	557
10/29-9/30	34	0	0	97	4	368	503
10/30-9/31	29	0	0	85	4	332	450
10/31-9/32		0	0	0	4	300	304
10/32-9/33						273	273
10/33-9/34						246	246
10/34-9/35						228	228
10/35-9/36						207	207
10/36-9/37						188	188
10/37-9/38						170	170
10/38-9/39						154	154
10/39-9/40						139	139
10/40-9/41						125	125
10/41-9/42						114	114
10/42-9/43						103	103
10/43-9/44						93	93
10/44-9/45						84	84
10/45-9/46						76	76
10/46-9/47						69	69
10/47-9/48						62	62
10/48-9/49						57	57
10/49-9/50							
Total	10,289	2,286	120	19,647	7,921	42,359	82,622

The first seven rows for each disease are actual data from Exhibit 3 Page 3 Table 9. For 10/07-9/08 the number of claims paid in the last quarter is assumed to be the same as the number paid in the prior quarter. For RECA, the 10/08-9/09 fiscal year is calculated as the number of cases approved from 10/07-9/08 from Table 1 plus a correction term of 1/5 of the difference in the number of cases approved from 7/01 through 9/07 from Table 1 and the number of cases approved from 7/01 through 9/08 from the first seven rows of this table. This is based on an assumption that RECA cases are paid one year after they are filed. The remaining fiscal years are calculated as the number of claims approved in the prior year with fiscal years through 10/12-9/13 containing the correction term.

The remaining Part B diseases are similar except that the assumption used is that a case is paid two years after it is filed for BD, CS, CN-NONSEC and one year for CN-SEC. The correction term is spread over 5 years for BD and CN-NONSEC and one year for CS and two years for CN-SEC (70% first year and 30% second year). Part E claims are assumed to be paid 4 years after they are filed (2 years from filing to approval and 2 years duration of payments). The correction term for Part E is spread over 10 years. An additional adjustment of 600 claims is deducted from 10/08-9/09 and added to the next year.

The number of BD cases includes BS cases paid and the number of RECA cases includes cases from all other otherwise non-covered diseases.

Table 3

ESTIMATED CASES ELIGIBLE FOR MEDICAL EXPENSES

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
Filing Date	RECA	BD	CS	CN - SEC	CN-NON SEC	BS	PART B NEW MEDICAL	PART E NEW MEDICAL	PART B ONGOING MEDICAL	PART E ONGOING MEDICAL
7/01-9/01	38	0	1	12	0	0	51	0	51	0
10/01-9/02	599	324	18	505	0	144	1,590	0	1,638	0
10/02-9/03	276	238	9	333	26	415	1,297	0	2,846	0
10/03-9/04	306	140	4	199	143	113	905	0	3,592	0
10/04-9/05	381	99	8	223	317	76	1,104	1	4,490	1
10/05-9/06	343	103	6	421	536	62	1,471	51	5,697	52
10/06-9/07	729	70	5	406	461	180	1,851	530	7,207	579
10/07-9/08	391	76	5	556	291	192	1,511	1,033	8,281	1,581
10/08-9/09	290	65	4	808	350	117	1,634	744	9,402	2,237
10/09-9/10	262	45	4	600	278	67	1,256	655	10,064	2,765
10/10-9/11	228	37	3	406	204	57	935	527	10,345	3,131
10/11-9/12	197	31	3	360	180	48	819	417	10,470	3,360
10/12-9/13	171	26	3	320	160	41	721	399	10,466	3,551
10/13-9/14	154	8	3	284	64	33	546	358	10,261	3,682
10/14-9/15	134	6	3	251	51	28	473	322	9,971	3,761
10/15-9/16	116	4	1	223	41	24	409	289	9,611	3,794
10/16-9/17	101	4	0	198	33	20	356	259	9,197	3,786
10/17-9/18	88	2	0	175	26	16	307	232	8,739	3,742
10/18-9/19	76	2	0	156	22	13	269	233	8,254	3,692
10/19-9/20	66	2	0	138	18	12	236	211	7,751	3,616
10/20-9/21	58	2	0	123	14	10	207	190	7,239	3,515
10/21-9/22	51	2	0	108	11	8	180	172	6,723	3,395
10/22-9/23	44	0	0	97	9	8	158	156	6,214	3,260
10/23-9/24	38	0	0	86	7	7	138	141	5,714	3,114
10/24-9/25	33	0	0	76	6	4	119	128	5,228	2,959
10/25-9/26	29	0	0	67	4	4	104	116	4,761	2,800
10/26-9/27	25	0	0	60	4	4	93	105	4,318	2,637
10/27-9/28	21	0	0	53	3	4	81	94	3,898	2,472
10/28-9/29	20	0	0	47	2	4	73	86	3,506	2,311
10/29-9/30	17	0	0	42	2	4	65	77	3,141	2,151
10/30-9/31	15	0	0	37	2	0	54	70	2,800	1,996
10/31-9/32		0	0	0	2	0	2	63	2,441	1,845
10/32-9/33								57	2,115	1,700
10/33-9/34								52	1,823	1,562
10/34-9/35								48	1,562	1,432
10/35-9/36								44	1,333	1,310
10/36-9/37								40	1,131	1,197
10/37-9/38								36	955	1,091
10/38-9/39								32	802	992
10/39-9/40								29	671	902
10/40-9/41								26	559	819
10/41-9/42								24	463	744
10/42-9/43								22	382	675
10/43-9/44								20	313	613
10/44-9/45								18	255	556
10/45-9/46								16	207	504
10/46-9/47								15	167	457
10/47-9/48								13	134	414
10/48-9/49								12	107	376
10/49-9/50								8	84	330
10/50-9/51								6	66	288
10/51-9/52								5	51	252
10/52-9/53								3	39	219
10/53-9/54								3	30	190
10/54-9/55								2	22	164
10/55-9/56								1	16	141
10/56-9/57								1	12	121
10/57-9/58								1	8	104
10/58-9/59								1	6	88
10/59-9/60								1	4	74
Total	5,297	1,286	80	7,370	3,267	1,715	19,015	8,163	217,633	93,100

The first seven rows of the new medical are from Exhibit 3 Table 10. The third quarter 2008 is estimated to be the same as the prior quarter.

For each Part B disease, the number of new cases eligible for medical payments is the estimated number of paid cases from Exhibit 5 Table 1 times the percentage filed by a living employee from Exhibit 1 Page 2 Table 3 times a mortality factor based on the assumption that the percentage of living employees filing claims will decrease over time.

The age at filing a claim is assumed to be 67. The claimants from the prior year are 68 and 2 years prior 69, etc. The probabilities of living an additional year are from Exhibit 1 Table 4.

For Part E, the number of new cases eligible for medical payments is the estimated number of paid cases from Exhibit 5 Table 2 times the percentage filed by a living employee from Exhibit 1 Page 2 Table 3 times a mortality factor based on the assumption that the percentage of living employees filing claims will decrease over time times a factor from Exhibit 1 page 2 Table 6. This factor is used because many Part E claims are also Part B claims and the medical is already counted in Part B.

The ongoing medical is estimated as the new medical plus each prior years new medical with a mortality factor applied.

Part B medical in column (8) is the sum of columns (2) through (7).

Assumes that a claimant is eligible for medical treatment in the same year as the claim is paid.

ESTIMATED DOLLARS PAID BY FISCAL YEAR

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)	(13) = (9) + (12) COMBINED PARTS B AND E TOTAL
Paid Fisc Yr	RECA	BD	CS	CN - SEC	CN-NON SEC	BS	PART B MEDICAL	PART B TOTAL	PART E COMPENSATION	PART E MEDICAL	PART E TOTAL	PARTS B AND E TOTAL
7/01-9/01	2,800,000	150,000	150,000	5,100,000	0	0	-1,149,955	7,050,045	0	-67,150	-67,150	\$6,982,895
10/01-9/02	89,445,000	60,161,586	3,900,000	194,700,000	450,000	0	3,822,538	352,479,124	0	0	0	\$352,479,124
10/02-9/03	38,822,020	59,163,006	2,400,000	185,250,000	20,700,000	0	14,738,995	321,074,021	0	0	0	\$321,074,021
10/03-9/04	28,870,000	44,783,172	750,000	98,500,000	75,412,500	0	23,002,343	271,318,015	0	0	0	\$271,318,015
10/04-9/05	86,344,840	36,075,000	1,800,000	115,470,000	147,287,500	0	32,552,048	419,529,388	200,008,207	225,099	200,233,306	\$619,762,694
10/05-9/06	105,130,556	29,550,000	1,050,000	202,736,449	203,082,947	0	39,493,165	581,043,116	279,796,075	2,139,077	281,935,152	\$862,978,268
10/06-9/07	129,197,071	23,360,163	1,500,000	217,264,643	172,997,273	0	57,457,264	601,776,414	366,649,214	5,007,991	371,657,205	\$973,433,619
10/07-9/08	87,207,952	20,030,500	1,200,000	303,560,649	106,955,071	0	66,085,632	585,039,805	435,534,763	6,149,068	441,683,831	\$1,026,723,636
10/08-9/09	85,200,000	18,900,000	1,050,000	278,550,000	106,950,000	0	84,618,000	575,268,000	505,791,000	20,133,000	525,924,000	\$1,101,192,000
10/09-9/10	77,100,000	13,050,000	900,000	207,000,000	85,050,000	0	96,010,560	479,110,560	445,016,000	26,378,100	471,394,100	\$950,504,660
10/10-9/11	66,900,000	10,800,000	600,000	140,100,000	62,400,000	0	104,608,640	385,408,640	358,215,000	31,660,672	389,875,672	\$775,284,312
10/11-9/12	57,900,000	8,850,000	600,000	124,200,000	55,050,000	0	112,227,930	358,827,930	283,283,000	36,015,840	319,298,840	\$678,126,770
10/12-9/13	50,100,000	7,500,000	600,000	110,400,000	48,900,000	0	118,914,692	336,414,692	270,842,000	40,346,462	311,188,462	\$647,603,154
10/13-9/14	45,300,000	2,400,000	600,000	97,950,000	19,500,000	0	123,583,484	289,333,484	243,529,000	44,346,008	287,875,008	\$577,208,492
10/14-9/15	39,450,000	1,800,000	600,000	86,700,000	15,600,000	0	127,299,757	271,449,757	218,647,000	48,016,687	266,663,687	\$538,113,444
10/15-9/16	34,200,000	1,200,000	300,000	76,800,000	12,600,000	0	130,065,663	255,165,663	196,196,000	51,344,202	247,540,202	\$502,705,865
10/16-9/17	29,550,000	1,200,000	0	68,400,000	10,050,000	0	131,930,965	241,130,965	175,890,000	54,310,170	230,200,170	\$471,331,135
10/17-9/18	25,950,000	600,000	0	60,300,000	8,100,000	0	132,876,495	227,826,495	157,586,000	56,897,110	214,483,110	\$442,309,605
10/18-9/19	22,350,000	600,000	0	53,700,000	6,600,000	0	133,037,972	216,287,972	158,158,000	59,507,656	217,665,656	\$433,953,628
10/19-9/20	19,350,000	600,000	0	47,550,000	5,400,000	0	132,425,835	205,325,835	143,143,000	61,779,360	204,922,360	\$410,248,195
10/20-9/21	16,950,000	600,000	0	42,300,000	4,350,000	0	131,098,290	195,298,290	129,415,000	63,656,650	193,071,650	\$388,369,940
10/21-9/22	14,850,000	600,000	0	37,350,000	3,450,000	0	129,054,708	185,304,708	116,974,000	65,170,420	182,144,420	\$367,449,128
10/22-9/23	12,900,000	0	0	33,300,000	2,700,000	0	126,442,472	175,342,472	105,963,000	66,334,480	172,297,480	\$347,639,952
10/23-9/24	11,250,000	0	0	29,700,000	2,250,000	0	123,245,266	166,445,266	95,953,000	67,165,866	163,118,866	\$329,564,132
10/24-9/25	9,600,000	0	0	26,100,000	1,800,000	0	119,527,764	157,027,764	86,801,000	67,651,617	154,452,617	\$311,480,381
10/25-9/26	8,400,000	0	0	23,100,000	1,350,000	0	115,382,835	148,232,835	78,507,000	67,858,000	146,365,000	\$294,597,835
10/26-9/27	7,200,000	0	0	20,700,000	1,200,000	0	110,925,102	140,025,102	71,071,000	67,741,893	138,812,893	\$278,837,995
10/27-9/28	6,150,000	0	0	18,300,000	1,050,000	0	106,142,540	131,642,540	64,207,000	67,312,560	131,519,560	\$263,162,100
10/28-9/29	5,850,000	0	0	16,050,000	600,000	0	101,197,184	123,697,184	58,201,000	66,704,704	124,905,704	\$248,602,888
10/29-9/30	5,100,000	0	0	14,550,000	600,000	0	96,102,036	116,352,036	52,624,000	65,811,996	118,435,996	\$234,788,032
10/30-9/31	4,350,000	0	0	12,750,000	600,000	0	90,809,600	108,509,600	47,476,000	64,734,272	112,210,272	\$220,719,872
10/31-9/32	0	0	0	0	600,000	0	83,916,698	84,516,698	42,900,000	63,427,410	106,327,410	\$190,844,108
10/32-9/33	0	0	0	0	0	0	77,070,600	77,070,600	39,039,000	61,948,000	100,987,000	\$178,057,600
10/33-9/34	0	0	0	0	0	0	70,417,021	70,417,021	35,178,000	60,335,374	95,513,374	\$165,930,395
10/34-9/35	0	0	0	0	0	0	63,954,528	63,954,528	32,604,000	58,631,808	91,235,808	\$155,190,336
10/35-9/36	0	0	0	0	0	0	57,853,533	57,853,533	29,601,000	56,855,310	86,456,310	\$144,309,840
10/36-9/37	0	0	0	0	0	0	52,031,655	52,031,655	26,884,000	55,067,985	81,951,985	\$133,983,640
10/37-9/38	0	0	0	0	0	0	46,570,575	46,570,575	24,310,000	53,202,615	77,512,615	\$124,083,190
10/38-9/39	0	0	0	0	0	0	41,456,182	41,456,182	22,022,000	51,277,472	73,299,472	\$114,755,654
10/39-9/40	0	0	0	0	0	0	36,766,103	36,766,103	19,877,000	49,423,286	69,300,286	\$106,066,389
10/40-9/41	0	0	0	0	0	0	32,466,720	32,466,720	17,875,000	47,567,520	65,442,520	\$97,909,240
10/41-9/42	0	0	0	0	0	0	28,504,595	28,504,595	16,302,000	45,804,360	62,106,360	\$90,610,955
10/42-9/43	0	0	0	0	0	0	24,928,938	24,928,938	14,729,000	44,049,825	58,778,825	\$83,707,763
10/43-9/44	0	0	0	0	0	0	21,651,775	21,651,775	13,299,000	42,404,275	55,703,275	\$77,355,050
10/44-9/45	0	0	0	0	0	0	18,697,875	18,697,875	12,012,000	40,768,700	52,780,700	\$71,478,575
10/45-9/46	0	0	0	0	0	0	16,089,075	16,089,075	10,868,000	39,173,400	50,041,400	\$66,130,475
10/46-9/47	0	0	0	0	0	0	13,758,796	13,758,796	9,867,000	37,651,316	47,518,316	\$61,277,112
10/47-9/48	0	0	0	0	0	0	11,702,488	11,702,488	8,866,000	36,155,448	45,021,448	\$56,723,936
10/48-9/49	0	0	0	0	0	0	9,905,097	9,905,097	8,151,000	34,806,696	42,957,696	\$52,862,793
10/49-9/50	0	0	0	0	0	0	8,242,584	8,242,584	0	32,381,580	32,381,580	\$40,624,164
10/50-9/51	0	0	0	0	0	0	6,864,858	6,864,858	0	29,955,744	29,955,744	\$36,820,602
10/51-9/52	0	0	0	0	0	0	5,622,954	5,622,954	0	27,784,008	27,784,008	\$33,406,962
10/52-9/53	0	0	0	0	0	0	4,557,891	4,557,891	0	25,594,311	25,594,311	\$30,152,202
10/53-9/54	0	0	0	0	0	0	3,716,430	3,716,430	0	23,537,390	23,537,390	\$27,253,820
10/54-9/55	0	0	0	0	0	0	2,888,908	2,888,908	0	21,535,496	21,535,496	\$24,424,404
10/55-9/56	0	0	0	0	0	0	2,227,088	2,227,088	0	19,626,213	19,626,213	\$21,853,301
10/56-9/57	0	0	0	0	0	0	1,770,540	1,770,540	0	17,852,945	17,852,945	\$19,623,485
10/57-9/58	0	0	0	0	0	0	1,251,184	1,251,184	0	16,265,392	16,265,392	\$17,516,576
10/58-9/59	0	0	0	0	0	0	994,686	994,686	0	14,588,728	14,588,728	\$15,583,414
10/59-9/60	0	0	0	0	0	0	702,912	702,912	0	13,003,872	13,003,872	\$13,706,784
TOTAL	\$1,223,767,439	\$341,973,426	\$18,000,000	\$2,948,431,741	\$1,183,635,291	\$0	\$3,660,112,109	\$9,375,920,006	\$5,729,860,259	\$2,395,008,289	\$8,124,868,548	\$17,500,788,554

Note that benefits paid for RECA claims includes the amounts paid on behalf of the DOJ from the last column of Exhibit 3 Page 3 Table 8. RECA includes EEOIC payments on otherwise non-covered diseases.

The first seven rows are actual payments from Exhibit 3 Page 3 Table 8. The row for fiscal year 10/07-9/08 is estimated based on 3 quarters of actual data and an estimate for the third quarter 2008. The estimate of the amount paid in fiscal year 10/07-9/08 is not included in the estimate of future liability as of 9/2008. The remaining rows are the number of estimated claims paid from Exhibit 5 Table 2 times the amount of the benefit based on the disease. For medical, the benefit amount by year is from Exhibit 1 Page 2 Table 5.

Assumption Sensitivity Analysis

This exhibit is used to show the impact of varying some of the major assumptions used in the analysis.

		Undiscounted Future Liability			Discounted Future Liability			Percentage Change In Total Discounted Future Liability
		Part B	Part E	Total	Part B	Part E	Total	
Current Assumptions		\$6,236,610,079	\$6,829,426,204	\$13,066,036,283	\$4,043,713,292	\$4,055,605,311	\$8,099,318,603	
Number of Claims Filed								
Current	Selected slope of fitted curve	6,236,610,079	6,829,426,204	13,066,036,283	4,043,713,292	4,055,605,311	8,099,318,603	0.0%
RECA	-0.0350							
BD	-0.0800							
CS	-0.0450							
CN - SEC	-0.0300							
CN - NONSEC	-0.0550							
BS	-0.0434							
PART E	-0.0250							
More claims	Add .01 to slope	18,881,984,452	12,383,274,273	31,265,258,725	9,836,205,797	6,045,613,213	15,881,819,010	96.1%
RECA	-0.0250							
BD	-0.0700							
CS	-0.0350							
CN - SEC	-0.0200							
CN - NONSEC	-0.0450							
BS	-0.0334							
PART E	-0.0150							
Fewer claims	Subtract .01 from slope	4,540,180,265	4,552,987,905	9,093,168,170	3,105,471,512	3,084,067,378	6,189,538,891	-23.6%
RECA	-0.0450							
BD	-0.0900							
CS	-0.0550							
CN - SEC	-0.0400							
CN - NONSEC	-0.0650							
BS	-0.0534							
PART E	-0.0350							
Medical Inflation Rate								
Current	6%	6,236,610,079	6,829,426,204	13,066,036,283	4,043,713,292	4,055,605,311	8,099,318,603	0.0%
	8%	7,417,934,166	8,179,319,495	15,597,253,661	4,495,190,043	4,416,284,788	8,911,474,831	10.0%
	4%	5,431,993,973	6,042,688,138	11,474,682,111	3,712,176,151	3,819,600,191	7,531,776,342	-7.0%
Medical Cost Per Case B and E								
Current	\$9,000	6,236,610,079	6,829,426,204	13,066,036,283	4,043,713,292	4,055,605,311	8,099,318,603	0.0%
	\$9,900	6,579,022,171	7,067,584,576	13,646,606,747	4,226,866,636	4,151,100,944	8,377,967,580	3.4%
	\$8,100	5,894,193,488	6,591,268,757	12,485,462,245	3,860,557,523	3,960,108,362	7,820,665,885	-3.4%
Approval Rates								
Current		6,236,610,079	6,829,426,204	13,066,036,283	4,043,713,292	4,055,605,311	8,099,318,603	0.0%
RECA	95%							
BD	53%							
CS	18%							
CN - SEC	77%							
CN - NONSEC	25%							
BS	56%							
PART E	40%							
10% Higher		\$7,200,825,124	\$7,702,866,260	\$14,903,691,384	4,743,832,384	4,601,360,578	9,345,192,962	15.4%
RECA	100%							
BD	58%							
CS	20%							
CN - SEC	85%							
CN - NONSEC	28%							
BS	62%							
PART E	44%							
10% Lower		\$5,215,321,998	\$5,953,888,081	11,169,210,079	\$3,310,845,522	\$3,508,335,019	\$6,819,180,541	-15.8%
RECA	86%							
BD	48%							
CS	16%							
CN - SEC	69%							
CN - NONSEC	23%							
BS	50%							
PART E	36%							
Interest Rate used to Discount Reserves								
Current	4.770%	6,236,610,079	6,829,426,204	13,066,036,283	4,043,713,292	4,055,605,311	8,099,318,603	0.0%
	5.770%	6,236,610,079	6,829,426,204	13,066,036,283	3,765,747,156	3,742,916,032	7,508,663,187	-7.3%
	3.770%	6,236,610,079	6,829,426,204	13,066,036,283	4,369,485,851	4,433,957,071	8,803,442,922	8.7%